Renal	I
artery	I
stenosis	I
-	O
an	O
update	O
.	O

Renal	I
artery	I
stenosis	I
(	O
RAS	I
)	O
is	O
a	O
common	O
form	O
of	O
peripheral	I
arterial	I
disease	I
.	O

The	O
most	O
common	O
cause	O
of	O
RAS	I
is	O
atherosclerosis	I
.	O

It	O
is	O
predominantly	O
unilateral	O
.	O

The	O
pathophysiologic	I
mechanism	O
stems	O
from	O
renal	I
underperfusion	I
resulting	O
in	O
the	O
activation	O
of	O
the	O
renin	I
-	I
angiotensin-aldosterone	I
pathway	I
.	O

Even	O
though	O
the	O
majority	O
of	O
patients	I
with	O
RAS	I
are	O
asymptomatic	I
,	O
it	O
can	O
clinically	I
present	O
with	O
hypertension	I
,	O
nephropathy	I
and	O
congestive	I
heart	I
failure	I
.	O

This	O
progressive	O
disease	I
can	O
lead	O
to	O
resistant	O
hypertension	I
and	O
end	O
stage	O
kidney	I
failure	I
.	O

Screening	O
patients	I
for	O
RAS	I
with	O
either	O
Doppler	I
ultrasonography	I
,	O
computed	O
tomographic	I
angiography	I
,	O
or	O
magnetic	I
resonance	I
angiography	I
is	O
preferred	O
.	O

Adequate	O
blood	I
pressure	I
control	O
,	O
goal-directed	O
lipid-lowering	I
therapy	I
,	O
smoking	O
cessation	O
,	O
and	O
other	O
preventive	O
measures	O
form	O
the	O
foundation	O
of	O
management	O
of	O
patients	I
with	O
RAS	I
.	O

Catheter-based	I
percutaneous	I
revascularization	I
with	O
angioplasty	I
and	O
stenting	I
showed	O
modest	O
clinical	I
benefit	O
for	O
patients	I
in	O
small	O
retrospective	O
studies	O
,	O
but	O
data	O
from	O
randomized	I
clinical	I
trials	O
failed	O
to	O
confirm	O
these	O
beneficial	O
results	O
.	O

The	O
current	O
ongoing	O
Cardiovascular	I
Outcomes	I
in	O
Renal	I
Atherosclerotic	I
Lesions	I
(	O
CORAL	O
)	O
trial	O
may	O
provide	O
more	O
concrete	O
data	O
regarding	O
the	O
role	O
of	O
stenting	I
in	O
RAS	I
.	O

Surgical	I
revascularization	I
is	O
considered	O
only	O
if	O
catheter-based	I
revascularization	I
is	O
unsuitable	O
or	O
unsuccessful	O
.	O

The	O
American	O
College	O
of	O
Cardiology	I
/	O
American	O
Heart	I
Association	O
guidelines	O
on	O
evaluation	O
and	O
management	O
of	O
patients	I
with	O
RAS	I
provide	O
the	O
framework	O
for	O
determining	O
individualized	O
assessment	O
and	O
treatment	O
plans	O
for	O
patients	I
with	O
RAS	I
.	O

Extracorporeal	I
membrane	I
oxygenation	I
as	O
bridge	O
to	O
recovery	O
in	O
infarction-related	I
refractory	I
right	I
heart	I
failure	I
.	O

HISTORY	O
AND	O
CLINICAL	I
FINDINGS	O
:	O

We	O
present	O
a	O
41-year-old	O
man	O
with	O
cardiac	I
arrest	I
in	O
need	O
of	O
cardiopulmonary	I
resuscitation	I
(	O
CPR	I
)	O
with	O
the	O
diagnosis	I
of	O
a	O
posterior	I
wall	I
infarction	I
,	O
who	O
was	O
hospitalized	I
in	O
our	O
cardiac	I
centre	O
.	O

INVESTIGATIONS	O
:	O

The	O
cardiac	I
catheterization	I
showed	O
a	O
thrombotic	I
obstruction	I
of	O
the	O
right	I
coronary	I
artery	I
.	O

After	O
percutaneous	I
coronary	I
revascularization	I
a	O
hemodynamically	I
stable	I
situation	O
could	O
be	O
achieved	O
and	O
the	O
patient	I
was	O
admitted	O
to	O
the	O
intensive	I
care	I
unit	I
(	O
ICU	I
)	O
.	O

TREATMENT	O
AND	O
CLINICAL	I
COURSE	O
:	O

The	O
patient	I
became	O
again	O
hemodynamically	I
unstable	O
and	O
a	O
CPR	I
was	O
required	O
.	O

Based	O
on	O
the	O
acute	I
right	I
heart	I
failure	I
with	O
therapy	I
refractory	I
cardiogenic	I
shock	I
we	O
decided	O
within	O
our	O
heart	I
team	O
for	O
an	O
extra	I
corporeal	I
membrane	I
oxygenation	I
(	O
ECMO	I
)	O
applied	O
during	O
CPR	I
in	O
the	O
ICU	I
.	O

The	O
extracorporeal	I
support	I
was	O
needed	O
for	O
three	O
days	O
.	O

Seven	O
days	O
after	O
the	O
emergency	O
cardiac	I
catheterization	I
the	O
patient	I
was	O
extubated	I
and	O
transferred	O
to	O
our	O
intermediate	O
care	O
.	O

CONCLUSION	O
:	O

Extracorporeal	I
life	I
support	I
is	O
feasible	O
und	O
effective	O
for	O
bridging	O
therapy	I
in	O
patients	I
with	O
acute	I
ischemic	I
right	I
heart	I
failure	I
with	O
refractory	I
cardiogenic	I
shock	I
and	O
successful	O
reperfusion	I
therapy	I
.	O

Frailty	I
and	O
risk	O
for	O
heart	I
failure	I
in	O
older	O
adults	O
:	O
the	O
health	I
,	O
aging	O
,	O
and	O
body	O
composition	O
study	O
.	O

OBJECTIVE	O
:	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
association	O
between	O
frailty	I
and	O
risk	O
for	O
heart	I
failure	I
(	O
HF	I
)	O
in	O
older	O
adults	O
.	O

BACKGROUND	O
:	O

Frailty	I
is	O
common	O
in	O
the	O
elderly	O
and	O
is	O
associated	O
with	O
adverse	O
health	I
outcomes	I
.	O

Impact	O
of	O
frailty	I
on	O
HF	I
risk	O
is	O
not	O
known	O
.	O

METHODS	O
:	O

We	O
assessed	O
the	O
association	O
between	O
frailty	I
,	O
using	O
the	O
Health	I
ABC	O
Short	O
Physical	I
Performance	O
Battery	O
(	O
HABC	O
Battery	O
)	O
and	O
the	O
Gill	O
index	O
,	O
and	O
incident	O
HF	I
in	O
2825	O
participants	O
aged	O
70	O
to	O
79	O
years	O
.	O

RESULTS	O
:	O

Mean	O
age	O
of	O
participants	O
was	O
74	O
±	O
3	O
years	O
;	O
48	O
%	O
were	O
men	O
and	O
59	O
%	O
were	O
white	O
.	O

During	O
a	O
median	O
follow	I
up	I
of	O
11.4	O
(	O
7.1	O
-	O
11.7	O
)	O
years	O
,	O
466	O
participants	O
developed	O
HF	I
.	O

Compared	O
to	O
non-frail	I
participants	O
,	O
moderate	O
(	O
HR	I
1.36	O
,	O
95	O
%	O
CI	I
1.08	O
-	O
1.71	O
)	O
and	O
severe	O
frailty	I
(	O
HR	I
1.88	O
,	O
95	O
%	O
CI	I
1.02	O
-	O
3.47	O
)	O
by	O
Gill	O
index	O
was	O
associated	O
with	O
a	O
higher	O
risk	O
for	O
HF	I
.	O

HABC	O
Battery	O
score	O
was	O
linearly	O
associated	O
with	O
HF	I
risk	O
after	O
adjusting	O
for	O
the	O
Health	I
ABC	O
HF	I
Model	O
(	O
HR	I
1.24	O
,	O
95	O
%	O
CI	I
1.13	O
-	O
1.36	O
per	O
SD	I
decrease	O
in	O
score	O
)	O
and	O
remained	O
significant	I
when	O
controlled	O
for	O
death	I
as	O
a	O
competing	O
risk	O
(	O
HR	I
1.30	O
;	O
95	O
%	O
CI	I
1.00	O
-	O
1.55	O
)	O
.	O

Results	O
were	O
comparable	O
across	O
age	O
,	O
sex	O
,	O
and	O
race	O
,	O
and	O
in	O
sub-groups	O
based	O
on	O
diabetes	I
mellitus	I
or	O
cardiovascular	I
disease	I
at	O
baseline	I
.	O

Addition	O
of	O
HABC	O
Battery	O
scores	O
to	O
the	O
Health	I
ABC	O
HF	I
Risk	O
Model	O
improved	O
discrimination	O
(	O
change	O
in	O
C-index	I
,	O
0.014	O
;	O
95	O
%	O
CI	I
0.018	O
-	O
0.010	O
)	O
and	O
appropriately	O
reclassified	O
13.4	O
%	O
(	O
net-reclassification-improvement	I
0.073	O
,	O
95	O
%	O
CI	I
0.021	O
-	O
0.125	O
;	O
P	I
=	O
.006	O
)	O
of	O
participants	O
(	O
8.3	O
%	O
who	O
developed	O
HF	I
and	O
5.1	O
%	O
who	O
did	O
not	O
)	O
.	O

CONCLUSIONS	O
:	O

Frailty	I
is	O
independently	O
associated	O
with	O
risk	O
of	O
HF	I
in	O
older	O
adults	O
.	O

Hemoglobin	I
,	O
exercise	O
training	O
,	O
and	O
health	I
status	O
in	O
patients	I
with	O
chronic	I
heart	I
failure	I
(	O
from	O
the	O
HF-ACTION	I
randomized	I
controlled	O
trial	O
)	O
.	O

Anemia	I
is	O
common	O
in	O
patients	I
with	O
chronic	I
heart	I
failure	I
(	O
HF	I
)	O
,	O
with	O
a	O
prevalence	I
ranging	O
from	O
10	O
%	O
to	O
56	O
%	O
,	O
and	O
may	O
be	O
a	O
risk	O
factor	O
for	O
poor	O
outcomes	I
.	O

Anemia	I
in	O
HF	I
remains	O
poorly	O
understood	O
,	O
with	O
significant	I
gaps	O
in	O
its	O
impact	O
on	O
health-related	I
quality	I
of	I
life	I
(	O
HRQoL	I
)	O
,	O
with	O
most	O
studies	O
in	O
HF	I
being	O
retrospective	O
or	O
from	O
registries	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
relation	O
of	O
hemoglobin	I
(	O
Hgb	I
)	O
with	O
HRQoL	I
and	O
training-induced	O
changes	O
in	O
HRQoL	I
in	O
a	O
cohort	O
of	O
patients	I
in	O
Heart	I
Failure	I
:	O
A	O
Controlled	O
Trial	O
Investigating	O
Outcomes	I
of	O
Exercise	O
Training	O
(	O
HF-ACTION	I
)	O
.	O

Using	O
data	O
from	O
HF-ACTION	I
,	O
a	O
randomized	I
controlled	O
trial	O
of	O
exercise	O
training	O
in	O
patients	I
with	O
HF	I
and	O
low	O
left	I
ventricular	I
ejection	I
fractions	I
,	O
HRQoL	I
was	O
measured	O
using	O
the	O
Kansas	O
City	O
Cardiomyopathy	I
Questionnaire	O
(	O
KCCQ	O
)	O
at	O
baseline	I
,	O
3	O
and	O
12	O
months	O
,	O
and	O
annually	O
up	O
to	O
4	O
years	O
.	O

Treatment	O
group	O
effects	O
on	O
HRQoL	I
were	O
estimated	O
using	O
linear	I
mixed	I
models	I
according	O
to	O
the	O
intention-to-treat	I
principle	O
.	O

It	O
was	O
hypothesized	O
that	O
baseline	I
Hgb	I
would	O
be	O
correlated	I
with	O
baseline	I
KCCQ	O
scales	O
and	O
that	O
Hgb	I
would	O
moderate	O
the	O
beneficial	O
effect	O
of	O
exercise	O
training	O
on	O
HRQoL	I
.	O

Hgb	I
level	O
was	O
not	O
significantly	I
correlated	I
with	O
baseline	I
HRQoL	I
.	O

Baseline	I
Hgb	I
did	O
not	O
moderate	O
the	O
beneficial	O
effect	O
of	O
exercise	O
training	O
on	O
KCCQ	O
overall	O
or	O
subscales	O
relative	O
to	O
usual	O
care	O
.	O

In	O
conclusion	O
,	O
in	O
the	O
HF-ACTION	I
cohort	O
,	O
there	O
was	O
no	O
correlation	I
with	O
baseline	I
Hgb	I
and	O
baseline	I
HRQoL	I
as	O
measured	O
by	O
the	O
KCCQ	O
.	O

In	O
addition	O
,	O
the	O
beneficial	O
effects	O
of	O
HRQoL	I
from	O
exercise	O
training	O
were	O
not	O
modulated	O
by	O
baseline	I
Hgb	I
.	O

Playing	O
it	O
safe	O
:	O
exercise	O
and	O
cardiovascular	I
health	I
.	O

Regular	O
physical	I
activity	O
controls	O
acquired	O
cardiovascular	I
risk	O
factors	O
such	O
as	O
obesity	I
,	O
diabetes	I
mellitus	I
,	O
hypertension	I
and	O
hyperlipidaemia	I
.	O

Exercise	O
is	O
generally	O
associated	O
with	O
a	O
50	O
%	O
reduction	O
in	O
adverse	I
events	I
from	O
coronary	I
artery	I
disease	I
(	O
CAD	I
)	O
.	O

The	O
benefits	O
of	O
exercise	O
extend	O
well	O
beyond	O
the	O
cardiovascular	I
system	O
.	O

Recent	O
evidence	O
suggests	O
that	O
exercise	O
prevents	O
cell	I
senescence	I
,	O
and	O
active	O
individuals	O
are	O
at	O
lower	O
risk	O
of	O
developing	O
certain	O
malignancies	O
including	O
cancer	O
of	O
the	O
prostate	O
and	O
the	O
colon	O
,	O
osteoporosis	I
,	O
depression	O
and	O
dementia	O
.	O

Individuals	O
who	O
exercise	O
regularly	O
extend	O
their	O
life	I
expectancy	I
by	O
three	O
to	O
seven	O
years	O
.	O

Healthy	I
individuals	O
should	O
engage	O
in	O
150	O
minutes	O
of	O
moderate-intensity	O
,	O
aerobic	O
exercise	O
per	O
week	O
.	O

Recent	O
studies	O
have	O
demonstrated	O
that	O
even	O
lower	O
volumes	O
of	O
exercise	O
below	O
these	O
recommendations	O
confer	O
health	I
benefits	O
,	O
which	O
is	O
highly	O
relevant	O
to	O
individuals	O
with	O
established	O
cardiac	I
disease	I
including	O
heart	I
failure	I
.	O

Sudden	O
cardiac	I
death	I
in	O
athletes	O
under	O
35	O
is	O
rare	O
with.estimates	O
ranging	O
from	O
1	O
in	O
50,000	O
to	O
1	O
in	O
200,000	O
.	O

Hereditary	I
and	O
congenital	I
abnormalities	O
of	O
the	O
heart	I
are	O
the	O
most	O
common	O
cause	O
of	O
nontraumatic	O
death	I
during	O
sport	O
in	O
young	O
athletes	O
.	O

In	O
middle-aged	O
recreational	O
athletes	O
more	O
than	O
90	O
%	O
of	O
sudden	O
cardiac	I
deaths	I
occur	O
in	O
males	O
and	O
more	O
than	O
90	O
%	O
are	O
caused	O
by	O
atherosclerotic	I
CAD	I
.	O

The	O
AHA	O
and	O
the	O
ESC	O
advocate	O
pre-participation	O
screening	O
of	O
young	O
athletes	O
.	O

The	O
ECG	I
has	O
the	O
ability	O
to	O
detect	O
congenital	I
accessory	O
pathways	O
and	O
ion	I
channelopathies	I
,	O
and	O
is	O
frequently	O
abnormal	O
in	O
individuals	O
with	O
cardiomyopathy	I
.	O

Screening	O
with	O
a	O
12-lead	O
ECG	I
in	O
older	O
athletes	O
is	O
of	O
limited	O
value	O
given	O
the	O
overwhelming	O
contribution	O
of	O
atherosclerotic	I
CAD	I
to	O
sudden	O
cardiac	I
death	I
.	O

Prognostic	I
value	O
of	O
indeterminable	O
anaerobic	I
threshold	I
in	O
heart	I
failure	I
.	O

BACKGROUND	O
:	O

In	O
patients	I
with	O
heart	I
failure	I
(	O
HF	I
)	O
,	O
during	O
maximal	O
cardiopulmonary	I
exercise	I
test	I
,	O
anaerobic	I
threshold	I
(	O
AT	I
)	O
is	O
not	O
always	O
identified	O
.	O

We	O
evaluated	O
whether	O
this	O
finding	O
has	O
a	O
prognostic	I
meaning	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O

We	O
recruited	O
and	O
prospectively	I
followed	I
up	I
,	O
in	O
14	O
dedicated	O
HF	I
units	O
,	O
3058	O
patients	I
with	O
systolic	I
(	O
left	I
ventricular	I
ejection	I
fraction	I
<	O
40	O
%	O
)	O
HF	I
in	O
stable	I
clinical	I
conditions	O
,	O
New	I
York	I
Heart	I
Association	I
class	I
I	I
to	O
III	I
,	O
who	O
underwent	O
clinical	I
,	O
laboratory	O
,	O
echocardiographic	I
,	O
and	O
cardiopulmonary	I
exercise	I
test	I
investigations	O
at	O
study	O
enrollment	O
.	O

We	O
excluded	O
921	O
patients	I
who	O
did	O
not	O
perform	O
a	O
maximal	O
exercise	O
,	O
based	O
on	O
lack	O
of	O
achievement	O
of	O
anaerobic	I
metabolism	I
(	O
peak	I
respiratory	I
quotient	I
≤1.05	O
)	O
.	O

Primary	O
study	O
end	I
point	I
was	O
a	O
composite	O
of	O
cardiovascular	I
death	I
and	O
urgent	O
cardiac	I
transplant	I
,	O
and	O
secondary	I
end	I
point	I
was	O
all-cause	O
death	I
.	O

Median	O
follow-up	I
was	O
3.01	O
(	O
1.39	O
-	O
4.98	O
)	O
years	O
.	O

AT	I
was	O
identified	O
in	O
1935	O
out	O
of	O
2137	O
patients	I
(	O
90.54	O
%	O
)	O
.	O

At	O
multivariable	I
logistic	I
analysis	I
,	O
failure	O
in	O
detecting	O
AT	I
resulted	O
significantly	I
in	O
reduced	O
peak	I
oxygen	I
uptake	I
and	O
higher	O
metabolic	I
exercise	I
and	O
cardiac	I
and	O
kidney	I
index	O
score	O
value	O
,	O
a	O
powerful	O
prognostic	I
composite	O
HF	I
index	I
(	O
P	I
<	O
0.001	O
)	O
.	O

At	O
multivariable	I
analysis	I
,	O
the	O
following	O
variables	O
were	O
significantly	I
associated	O
with	O
primary	O
study	O
end	I
point	I
:	O
peak	I
oxygen	I
uptake	I
(	O
%	O
pred	O
;	O
P	I
<	O
0.001	O
;	O
hazard	I
ratio	I
[	O
HR]=0.977	I
;	O
confidence	I
interval	I
[	O
CI]=0.97-0.98	I
)	O
,	O
ventilatory	I
efficiency	I
slope	I
(	O
P=0.01	I
;	O
HR=1.02	I
;	O
CI=1.01-1.03	I
)	O
,	O
hemoglobin	I
(	O
P	I
<	O
0.05	O
;	O
HR=0.931	I
;	O
CI=0.87-1.00	I
)	O
,	O
left	I
ventricular	I
ejection	I
fraction	I
(	O
P	I
<	O
0.001	O
;	O
HR=0.948	I
;	O
CI=0.94-0.96	I
)	O
,	O
renal	I
function	I
(	O
modification	O
of	O
diet	O
in	O
renal	I
disease	I
;	O
P	I
<	O
0.001	O
;	O
HR=0.990	I
;	O
CI=0.98-0.99	I
)	O
,	O
sodium	I
(	O
P	I
<	O
0.05	O
;	O
HR=0.967	I
;	O
CI=0.94-0.99	I
)	O
,	O
and	O
AT	I
nonidentification	O
(	O
P	I
<	O
0.05	O
;	O
HR=1.41	I
;	O
CI=1.06-1.89	I
)	O
.	O

Nonidentification	O
of	O
AT	I
remained	O
associated	O
to	O
prognosis	I
also	O
when	O
compared	O
with	O
metabolic	I
exercise	I
and	O
cardiac	I
and	O
kidney	I
index	O
score	O
(	O
P	I
<	O
0.01	O
;	O
HR=1.459	I
;	O
CI=1.09-1.10	I
)	O
.	O

Similar	O
results	O
were	O
obtained	O
for	O
the	O
secondary	O
study	O
end	I
point	I
.	O

CONCLUSIONS	O
:	O

The	O
inability	O
to	O
identify	O
AT	I
most	O
often	O
occurs	O
in	O
patients	I
with	O
severe	I
HF	I
,	O
and	O
it	O
has	O
an	O
independent	O
prognostic	I
role	O
in	O
HF	I
.	O

Randomized	I
trial	O
of	O
Nordic	O
walking	O
in	O
patients	I
with	O
moderate	I
to	O
severe	I
heart	I
failure	I
.	O

BACKGROUND	O
:	O

Patients	I
with	O
heart	I
failure	I
are	O
a	O
growing	O
population	O
within	O
cardiac	I
rehabilitation	I
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
,	O
through	O
a	O
single-centre	O
,	O
parallel-group	O
,	O
randomized	I
controlled	O
trial	O
,	O
the	O
effects	O
of	O
Nordic	O
walking	O
and	O
standard	O
cardiac	I
rehabilitation	I
care	O
on	O
functional	I
capacity	I
and	O
other	O
outcomes	I
in	O
patients	I
with	O
moderate	I
to	O
severe	I
heart	I
failure	I
.	O

METHODS	O
:	O

Between	O
2008	O
and	O
2009	O
,	O
54	O
patients	I
(	O
aged	O
62.4	O
±	O
11.4	O
years	O
)	O
with	O
heart	I
failure	I
(	O
mean	O
ejection	I
fraction	I
=	O
26.9	O
%	O
±	O
5.0	O
%	O
)	O
were	O
randomly	O
assigned	O
to	O
standard	O
cardiac	I
rehabilitation	I
care	O
(	O
n	O
=	O
27	O
)	O
or	O
Nordic	O
walking	O
(	O
n	O
=	O
27	O
)	O
;	O
both	O
groups	O
performed	O
200	O
to	O
400	O
minutes	O
of	O
exercise	O
per	O
week	O
for	O
12	O
weeks	O
.	O

The	O
primary	I
outcome	I
,	O
measured	O
after	O
12	O
weeks	O
,	O
was	O
functional	I
capacity	I
assessed	O
by	O
a	O
6-minute	I
walk	I
test	I
(	O
6MWT	I
)	O
.	O

RESULTS	O
:	O

Compared	O
with	O
standard	O
care	O
,	O
Nordic	O
walking	O
led	O
to	O
higher	O
functional	I
capacity	I
(	O
Δ	O
125.6	O
±	O
59.4	O
m	O
vs	O
Δ	O
57.0	O
±	O
71.3	O
m	O
travelled	O
during	O
6MWT	I
;	O
P	I
=	O
0.001	O
)	O
,	O
greater	O
self-reported	O
physical	I
activity	O
(	O
Δ	O
158.5	O
±	O
118.5	O
minutes	O
vs	O
Δ	O
155.5	O
±	O
125.6	O
minutes	O
;	O
P	I
=	O
0.049	O
)	O
,	O
increased	O
right	O
grip	O
strength	O
(	O
Δ	O
2.3	O
±	O
3.5	O
kg	O
vs	O
Δ	O
0.3	O
±	O
3.1	O
kg	O
;	O
P	I
=	O
0.026	O
)	O
,	O
and	O
fewer	O
depressive	O
symptoms	I
(	O
Hospital	I
Anxiety	O
and	O
Depression	O
Scale	O
score	O
=	O
Δ	O
-	O
1.7	O
±	O
2.4	O
vs	O
Δ	O
-	O
0.8	O
±	O
3.1	O
;	O
P	I
=	O
0.014	O
)	O
.	O

No	O
significant	I
differences	O
were	O
found	O
for	O
peak	O
aerobic	O
capacity	O
,	O
left-hand	O
grip	O
strength	O
,	O
body	O
weight	O
,	O
waist	O
circumference	O
,	O
or	O
symptoms	I
of	O
anxiety	O
.	O

CONCLUSIONS	O
:	O

Nordic	O
walking	O
was	O
superior	O
to	O
standard	O
cardiac	I
rehabilitation	I
care	O
in	O
improving	O
functional	I
capacity	I
and	O
other	O
important	O
outcomes	I
in	O
patients	I
with	O
heart	I
failure	I
.	O

This	O
exercise	O
modality	O
is	O
a	O
promising	O
alternative	O
for	O
this	O
population	O
.	O

Impact	O
of	O
carvedilol	I
and	O
metoprolol	I
on	O
inappropriate	O
implantable	I
cardioverter-defibrillator	I
therapy	I
:	O
the	O
MADIT-CRT	I
trial	O
(	O
Multicenter	O
Automatic	O
Defibrillator	I
Implantation	I
With	O
Cardiac	I
Resynchronization	I
Therapy	I
)	O
.	O

OBJECTIVES	O
:	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effects	O
of	O
carvedilol	I
and	O
metoprolol	I
on	O
the	O
endpoint	I
of	O
inappropriate	O
implantable	I
cardioverter-defibrillator	I
therapy	I
in	O
the	O
MADIT-CRT	I
(	O
Multicenter	O
Automatic	O
Defibrillator	I
Implantation	I
With	O
Cardiac	I
Resynchronization	I
Therapy	I
)	O
study	O
.	O

BACKGROUND	O
:	O

The	O
impact	O
of	O
carvedilol	I
and	O
metoprolol	I
on	O
inappropriate	O
therapy	I
in	O
heart	I
failure	I
patients	I
with	O
devices	O
has	O
not	O
yet	O
been	O
investigated	O
.	O

METHODS	O
:	O

All	O
patients	I
in	O
the	O
MADIT-CRT	I
study	O
who	O
received	O
a	O
device	O
(	O
N	O
=	O
1,790	O
)	O
were	O
identified	O
.	O

Using	O
time-dependent	O
Cox	I
regression	I
analysis	I
,	O
we	O
compared	O
patients	I
treated	O
with	O
different	O
types	O
of	O
beta-blockers	I
or	O
no	O
beta-blockers	I
on	O
the	O
primary	I
endpoint	I
of	O
inappropriate	O
therapy	I
,	O
delivered	O
as	O
antitachycardia	I
pacing	I
(	O
ATP	I
)	O
or	O
shock	I
therapy	I
.	O

Secondary	I
endpoints	I
were	O
inappropriate	O
therapy	I
due	O
to	O
atrial	I
fibrillation	I
and	O
atrial	I
tachyarrhythmias	I
,	O
also	O
evaluated	O
as	O
ATP	I
or	O
shock	I
therapy	I
.	O

RESULTS	O
:	O

Inappropriate	O
therapy	I
occurred	O
in	O
253	O
(	O
14	O
%	O
)	O
of	O
1,790	O
patients	I
during	O
a	O
follow-up	I
period	O
of	O
3.4	O
±	O
1.1	O
years	O
.	O

Treatment	O
with	O
carvedilol	I
was	O
associated	O
with	O
a	O
significantly	I
decreased	O
risk	O
of	O
inappropriate	O
therapy	I
compared	O
with	O
metoprolol	I
(	O
hazard	I
ratio	I
[	O
HR	I
]	O
:	O
0.64	O
[	O
95	O
%	O
confidence	I
interval	I
(	O
CI	I
)	O
:	O
0.48	O
to	O
0.85	O
]	O
;	O
p	I
=	O
0.002	O
)	O
.	O

The	O
reduction	O
in	O
risk	O
was	O
consistent	O
for	O
inappropriate	O
ATP	I
(	O
HR	I
:	O
0.66	O
[	O
95	O
%	O
CI	I
:	O
0.48	O
to	O
0.90	O
]	O
;	O
p	I
=	O
0.009	O
)	O
and	O
inappropriate	O
shock	I
therapy	I
(	O
HR	I
:	O
0.54	O
[	O
95	O
%	O
CI	I
:	O
0.36	O
to	O
0.80	O
]	O
;	O
p	I
=	O
0.002	O
)	O
.	O

The	O
risk	O
of	O
inappropriate	O
therapy	I
caused	O
by	O
atrial	I
fibrillation	I
was	O
also	O
reduced	O
in	O
patients	I
receiving	O
carvedilol	I
compared	O
with	O
metoprolol	I
(	O
HR	I
:	O
0.50	O
[	O
95	O
%	O
CI	I
:	O
0.32	O
to	O
0.81	O
]	O
;	O
p	I
=	O
0.004	O
)	O
.	O

General	O
use	O
of	O
beta-blockers	I
(	O
93	O
%	O
)	O
and	O
adherence	O
in	O
this	O
study	O
was	O
high	O
.	O

CONCLUSIONS	O
:	O

In	O
heart	I
failure	I
patients	I
undergoing	O
either	O
cardiac	I
resynchronization	I
therapy	I
with	O
a	O
defibrillator	I
or	O
with	O
an	O
implantable	I
cardioverter-defibrillator	I
device	I
,	O
carvedilol	I
was	O
associated	O
with	O
a	O
36	O
%	O
lower	O
rate	O
of	O
inappropriate	O
ATP	I
and	O
shock	I
therapy	I
compared	O
with	O
metoprolol	I
.	O

Inappropriate	O
therapy	I
due	O
to	O
atrial	I
fibrillation	I
was	O
associated	O
with	O
a	O
50	O
%	O
lower	O
rate	O
in	O
patients	I
receiving	O
carvedilol	I
compared	O
with	O
those	O
receiving	O
metoprolol	I
.	O

(	O
MADIT-CRT	I
:	O
Multicenter	O
Automatic	O
Defibrillator	I
Implantation	I
With	O
Cardiac	I
Resynchronization	I
Therapy	I
;	O
NCT00180271	O
)	O
.	O

Fully	I
Magnetically	I
Levitated	I
Left	I
Ventricular	I
Assist	I
System	I
for	O
Treating	O
Advanced	O
HF	I
:	O
A	O
Multicenter	O
Study	O
.	O

BACKGROUND	O
:	O

The	O
HeartMate	O
3	O
left	I
ventricular	I
assist	I
system	I
(	O
LVAS	I
)	O
is	O
intended	O
to	O
provide	O
long-term	O
support	O
to	O
patients	I
with	O
advanced	O
heart	I
failure	I
.	O

The	O
centrifugal	I
flow	I
pump	I
is	O
designed	O
for	O
enhanced	O
hemocompatibility	I
by	O
incorporating	O
a	O
magnetically	O
levitated	O
rotor	O
with	O
wide	O
blood-flow	I
paths	O
and	O
an	O
artificial	O
pulse	I
.	O

OBJECTIVES	O
:	O

The	O
aim	O
of	O
this	O
single-arm	O
,	O
prospective	I
,	O
multicenter	O
study	O
was	O
to	O
evaluate	O
the	O
performance	O
and	O
safety	O
of	O
this	O
LVAS	I
.	O

METHODS	O
:	O

The	O
primary	I
endpoint	I
was	O
6-month	O
survival	O
compared	O
with	O
INTERMACS	O
(	O
Interagency	O
Registry	O
for	O
Mechanically	O
Assisted	O
Circulatory	I
Support)-derived	I
performance	O
goal	O
.	O

Patients	I
were	O
adults	O
with	O
ejection	I
fraction	I
≤	O
25	O
%	O
,	O
cardiac	I
index	I
≤	O
2.2	O
l	O
/	O
min	O
/	O
m	O
(	O
2	O
)	O
without	O
inotropes	I
or	O
were	O
inotrope-dependent	O
on	O
optimal	O
medical	I
management	O
,	O
or	O
listed	O
for	O
transplant	I
.	O

RESULTS	O
:	O

Fifty	O
patients	I
were	O
enrolled	O
at	O
10	O
centers	O
.	O

The	O
indications	O
for	O
LVAS	I
support	O
were	O
bridge	I
to	I
transplantation	I
(	O
54	O
%	O
)	O
or	O
destination	I
therapy	I
(	O
46	O
%	O
)	O
.	O

At	O
6	O
months	O
,	O
88	O
%	O
of	O
patients	I
continued	O
on	O
support	O
,	O
4	O
%	O
received	O
transplants	I
,	O
and	O
8	O
%	O
died	O
.	O

Thirty-day	O
mortality	I
was	O
2	O
%	O
and	O
6-month	O
survival	O
92	O
%	O
,	O
which	O
exceeded	O
the	O
88	O
%	O
performance	O
goal	O
.	O

Support	O
with	O
the	O
fully	I
magnetically	I
levitated	I
LVAS	I
significantly	I
reduced	O
mortality	I
risk	O
by	O
66	O
%	O
compared	O
with	O
the	O
Seattle	O
Heart	I
Failure	I
Model-predicted	O
survival	O
of	O
78	O
%	O
(	O
p	I
=	O
0.0093	O
)	O
.	O

Key	O
adverse	I
events	I
included	O
reoperation	I
for	O
bleeding	I
(	O
14	O
%	O
)	O
,	O
driveline	I
infection	I
(	O
10	O
%	O
)	O
,	O
gastrointestinal	I
bleeding	I
(	O
8	O
%	O
)	O
,	O
and	O
debilitating	O
stroke	I
(	O
modified	O
Rankin	I
Score	I
>	O
3	O
)	O
(	O
8	O
%	O
)	O
.	O

There	O
were	O
no	O
pump	O
exchanges	O
,	O
pump	O
malfunctions	O
,	O
pump	I
thrombosis	I
,	O
or	O
hemolysis	I
events	O
.	O

New	I
York	I
Heart	I
Association	I
classification	I
,	O
6-min	I
walk	I
test	I
,	O
and	O
quality-of-life	I
scores	O
showed	O
progressive	O
and	O
sustained	O
improvement	O
.	O

CONCLUSIONS	O
:	O

The	O
results	O
show	O
that	O
the	O
fully	I
magnetically	I
levitated	I
centrifugal-flow	I
chronic	I
LVAS	I
is	O
safe	O
,	O
with	O
high	O
30-day	O
and	O
6-month	O
survival	O
rates	O
,	O
a	O
favorable	O
adverse	I
event	I
profile	O
,	O
and	O
improved	O
quality	I
of	I
life	I
and	O
functional	I
status	I
.	O

Improving	O
outcomes	I
in	O
patients	I
with	O
atrial	I
fibrillation	I
:	O
rationale	O
and	O
design	O
of	O
the	O
Early	O
treatment	O
of	O
Atrial	I
fibrillation	I
for	O
Stroke	I
prevention	O
Trial	O
.	O

BACKGROUND	O
:	O

Even	O
on	O
optimal	O
therapy	I
including	O
anticoagulation	I
and	O
rate	I
control	I
,	O
major	O
cardiovascular	I
complications	I
(	O
stroke	I
,	O
cardiovascular	I
death	I
,	O
and	O
acute	I
heart	I
failure	I
)	O
are	O
common	O
in	O
patients	I
with	O
atrial	I
fibrillation	I
(	O
AF	I
)	O
.	O

Conceptually	O
,	O
maintenance	O
of	O
sinus	I
rhythm	I
could	O
prevent	O
adverse	I
outcomes	I
related	O
to	O
AF	I
.	O

Rhythm	I
control	I
therapy	I
has	O
been	O
only	O
moderately	O
effective	O
in	O
published	O
trials	O
,	O
and	O
its	O
potential	O
benefit	O
was	O
offset	O
by	O
side	O
effects	O
of	O
repeated	O
interventions	O
.	O

RATIONALE	O
:	O

Rhythm	I
control	I
therapy	I
applied	O
early	O
after	O
the	O
first	O
diagnosis	I
of	O
AF	I
could	O
preserve	O
atrial	I
structure	O
and	O
function	O
and	O
maintain	O
sinus	I
rhythm	I
more	O
effectively	O
than	O
the	O
current	O
practice	O
of	O
delayed	O
rhythm	I
control	I
(	O
when	O
symptoms	I
persist	O
after	O
otherwise	O
effective	O
rate	I
control	I
)	O
.	O

Furthermore	O
,	O
catheter	I
ablation	I
and	O
new	O
antiarrhythmic	I
drugs	I
have	O
enhanced	O
the	O
potential	O
effectiveness	O
and	O
safety	O
of	O
rhythm	I
control	I
therapy	I
.	O

The	O
EAST	O
will	O
test	O
whether	O
an	O
early	O
,	O
modern	O
rhythm	I
control	I
therapy	I
can	O
reduce	O
cardiovascular	I
complications	I
in	O
AF	I
.	O

DESIGN	O
:	O

The	O
EAST	O
(	O
Early	O
treatment	O
of	O
Atrial	I
fibrillation	I
for	O
Stroke	I
prevention	O
Trial	O
)	O
will	O
randomize	I
approximately	O
3,000	O
patients	I
with	O
recent	O
onset	O
AF	I
at	O
risk	O
for	O
stroke	I
(	O
CHA₂DS₂VASc	I
score	I
≥2	O
)	O
to	O
either	O
guideline-mandated	O
usual	O
care	O
or	O
to	O
usual	O
care	O
plus	O
early	O
rhythm	I
control	I
therapy	I
in	O
a	O
prospective	I
,	O
randomized	I
,	O
open	O
,	O
blinded	O
outcome	I
assessment	O
trial	O
.	O

All	O
patients	I
will	O
be	O
followed	I
up	I
until	O
the	O
end	O
of	O
the	O
trial	O
for	O
the	O
composite	I
primary	I
outcome	I
of	O
cardiovascular	I
death	I
,	O
stroke	I
,	O
worsening	O
of	O
heart	I
failure	I
,	O
and	O
myocardial	I
infarction	I
.	O

Nights	O
spent	O
in	O
hospital	I
will	O
be	O
counted	O
as	O
a	O
coprimary	I
outcome	I
.	O

Usual	O
care	O
will	O
consist	O
of	O
anticoagulation	I
,	O
therapy	I
of	O
underlying	O
heart	I
disease	I
,	O
and	O
rate	I
control	I
as	O
an	O
initial	O
approach	O
.	O

Early	O
rhythm	I
control	I
therapy	I
will	O
consist	O
of	O
usual	O
care	O
plus	O
rhythm	I
control	I
therapy	I
by	O
antiarrhythmic	I
drugs	I
,	O
catheter	I
ablation	I
,	O
and	O
a	O
patient-operated	I
electrocardiographic	I
device	O
to	O
monitor	O
the	O
ongoing	O
rhythm	O
.	O

Key	O
secondary	I
outcomes	I
include	O
cognitive	O
function	O
and	O
quality	I
of	I
life	I
.	O

CONCLUSION	O
:	O

EAST	O
will	O
determine	O
whether	O
rhythm	I
control	I
therapy	I
,	O
when	O
applied	O
early	O
after	O
the	O
initial	O
diagnosis	I
of	O
AF	I
,	O
can	O
prevent	O
cardiovascular	I
complications	I
associated	O
with	O
AF	I
.	O

Impact	O
of	O
physician	I
continuity	O
on	O
death	I
or	O
urgent	O
readmission	I
after	O
discharge	I
among	O
patients	I
with	O
heart	I
failure	I
.	O

BACKGROUND	O
:	O

Early	O
physician	I
follow-up	I
after	O
discharge	I
is	O
associated	O
with	O
lower	O
rates	O
of	O
death	I
and	O
readmission	I
among	O
patients	I
with	O
heart	I
failure	I
.	O

We	O
explored	O
whether	O
physician	I
continuity	O
further	O
influences	O
outcomes	I
after	O
discharge	I
.	O

METHODS	O
:	O

We	O
used	O
data	O
from	O
linked	O
administrative	O
databases	O
for	O
all	O
adults	O
aged	O
20	O
years	O
or	O
more	O
in	O
the	O
province	O
of	O
Alberta	O
who	O
were	O
discharged	I
alive	O
from	O
hospital	I
between	O
January	O
1999	O
and	O
June	O
2009	O
with	O
a	O
first-time	O
diagnosis	I
of	O
heart	I
failure	I
.	O

We	O
used	O
Cox	I
proportional	I
hazard	I
models	I
with	O
time-dependent	O
covariates	I
to	O
analyze	O
the	O
effect	O
of	O
follow-up	I
with	O
a	O
familiar	O
physician	I
within	O
the	O
first	O
month	O
after	O
discharge	I
on	O
the	O
primary	I
outcome	I
of	O
death	I
or	O
urgent	O
all-cause	I
readmission	I
over	O
6	O
months	O
.	O

A	O
familiar	O
physician	I
was	O
defined	O
as	O
one	O
who	O
had	O
seen	O
the	O
patient	I
at	O
least	O
twice	O
in	O
the	O
year	O
before	O
the	O
index	O
admission	I
or	O
once	O
during	O
the	O
index	O
admission	I
.	O

RESULTS	O
:	O

In	O
the	O
first	O
month	O
after	O
discharge	I
,	O
5336	O
(	O
21.9	O
%	O
)	O
of	O
the	O
24	O
373	O
identified	O
patients	I
had	O
no	O
follow-up	I
visits	O
,	O
16	O
855	O
(	O
69.2	O
%	O
)	O
saw	O
a	O
familiar	O
physician	I
,	O
and	O
2182	O
(	O
9.0	O
%	O
)	O
saw	O
unfamiliar	O
physician	I
(	O
s	O
)	O
exclusively	O
.	O

The	O
risk	O
of	O
death	I
or	O
unplanned	O
readmission	I
during	O
the	O
6-month	O
observation	O
period	O
was	O
lower	O
among	O
patients	I
who	O
saw	O
a	O
familiar	O
physician	I
(	O
43.6	O
%	O
;	O
adjusted	O
hazard	I
ratio	I
[	O
HR	I
]	O
0.87	O
,	O
95	O
%	O
confidence	I
interval	I
[	O
CI	I
]	O
0.83	O
-	O
0.91	O
)	O
or	O
an	O
unfamiliar	O
physician	I
(	O
43.6	O
%	O
;	O
adjusted	O
HR	I
0.90	O
,	O
95	O
%	O
CI	I
0.83	O
-	O
0.97	O
)	O
for	O
early	O
follow-up	I
visits	O
,	O
as	O
compared	O
with	O
patients	I
who	O
had	O
no	O
follow-up	I
visits	O
(	O
62.9	O
%	O
)	O
.	O

Taking	O
into	O
account	O
all	O
follow-up	I
visits	O
over	O
the	O
6-month	O
period	O
,	O
we	O
found	O
that	O
the	O
risk	O
of	O
death	I
or	O
urgent	O
readmission	I
was	O
lower	O
among	O
patients	I
who	O
had	O
all	O
of	O
their	O
visits	O
with	O
a	O
familiar	O
physician	I
than	O
among	O
those	O
followed	O
by	O
unfamiliar	O
physicians	I
(	O
adjusted	O
HR	I
0.91	O
,	O
95	O
%	O
CI	I
0.85	O
-	O
0.98	O
)	O
.	O

INTERPRETATION	O
:	O

Early	O
physician	I
follow-up	I
after	O
discharge	I
and	O
physician	I
continuity	O
were	O
both	O
associated	O
with	O
better	O
outcomes	I
among	O
patients	I
with	O
heart	I
failure	I
.	O

Research	O
is	O
needed	O
to	O
explore	O
whether	O
physician	I
continuity	O
is	O
important	O
for	O
other	O
conditions	I
and	O
in	O
settings	O
other	O
than	O
recent	O
hospital	I
discharge	I
.	O

Epidemiology	I
and	O
treatment	O
of	O
chronic	I
heart	I
failure	I
;	O
use	O
of	O
bisoprolol	I
.	O

The	O
prevalence	I
of	O
chronic	I
heart	I
failure	I
in	O
Hungary	O
is	O
1.6	O
%	O
in	O
the	O
adult	O
population	O
,	O
but	O
it	O
occurs	O
in	O
15	O
-	O
20	O
%	O
of	O
subjects	O
over	O
80	O
years	O
of	O
age	O
.	O

The	O
base	O
of	O
treatment	O
of	O
heart	I
failure	I
is	O
the	O
blockade	O
of	O
the	O
neuro-hormonal	I
system	I
,	O
which	O
includes	O
the	O
use	O
of	O
angiotensin	I
converting	I
enzyme	I
inhibitors	I
(	O
angiotensin	I
receptor	I
blockers	I
in	O
case	O
of	O
angiotensin	I
converting	I
enzyme	I
inhibitors	I
intolerance	O
)	O
,	O
beta	I
receptor	I
blockers	I
and	O
mineralocorticoid	I
receptor	I
antagonists	I
.	O

Because	O
of	O
their	O
negative	O
inotropic	I
effect	I
,	O
beta	I
blockers	I
were	O
neglected	O
for	O
a	O
long	O
time	O
from	O
the	O
treatment	O
of	O
heart	I
failure	I
.	O

However	O
,	O
during	O
the	O
past	O
decades	O
several	O
studies	O
have	O
demonstrated	O
that	O
beta	I
blockers	I
decrease	O
mortality	I
in	O
patients	I
with	O
heart	I
failure	I
.	O

The	O
effectiveness	O
of	O
bisoprolol	I
in	O
reducing	O
mortality	I
has	O
also	O
also	O
been	O
documented	O
in	O
a	O
number	O
of	O
studies	O
.	O

Using	O
exercise	O
to	O
improve	O
quality	I
of	I
life	I
for	O
people	O
with	O
heart	I
failure	I
.	O

Abstract	O

In	O
the	O
current	O
economic	O
climate	O
within	O
the	O
NHS	O
,	O
behavioural-change	O
interventions	O
in	O
chronic	I
disease	I
such	O
as	O
exercise	O
programmes	O
will	O
be	O
time-limited	O
within	O
acute	I
hospital	I
facilities	O
.	O

The	O
challenge	O
is	O
to	O
deliver	O
cost-effective	O
,	O
participatory	O
,	O
population-specific	O
health	I
interventions	O
that	O
result	O
in	O
measurable	O
benefits	O
.	O

METHODOLOGY	O
:	O

A	O
mixed-methods	I
study	I
was	O
undertaken	O
to	O
assess	O
the	O
benefits	O
of	O
participation	O
in	O
a	O
structured	O
exercise	O
programme	O
for	O
patients	I
with	O
heart	I
failure	I
.	O

Primary	I
outcomes	I
were	O
improvements	O
in	O
functional	I
capacity	I
and	O
quality	I
of	I
life	I
.	O

Secondary	I
outcome	I
measures	O
related	O
to	O
patient	I
satisfaction	O
and	O
sustainability	O
of	O
the	O
intervention	O
post	O
study	O
.	O

RESULTS	O
:	O

Overall	O
significant	I
improvements	O
were	O
not	O
found	O
in	O
quality	I
of	I
life	I
or	O
functional	I
capacity	I
;	O
some	O
participants	O
demonstrated	O
significant	I
improvements	O
with	O
others	O
showing	O
minor	O
improvement	O
or	O
no	O
improvement	O
in	O
one	O
or	O
both	O
domains	O
.	O

CONCLUSIONS	O
:	O

Anecdotal	O
evidence	O
of	O
perceived	O
benefit	O
was	O
expressed	O
in	O
participant	O
satisfaction	O
responses	O
.	O

Secondary	I
outcomes	I
were	O
met	O
in	O
relation	O
to	O
sustainability	O
with	O
commissioning	O
of	O
hospital	I
-	O
and	O
community-based	O
programmes	O
on	O
completion	O
of	O
the	O
study	O
.	O

Hemodynamic	I
phenotype	I
of	O
the	O
failing	O
Fontan	I
in	O
an	O
adult	O
population	O
.	O

Fontan	I
failure	I
can	O
occur	O
even	O
with	O
normal	O
systolic	I
ventricular	I
function	I
and	O
often	O
in	O
the	O
context	O
of	O
significant	O
liver	I
disease	I
.	O

We	O
hypothesized	O
that	O
Fontan	I
failure	I
is	O
hemodynamically	I
distinct	O
from	O
traditional	O
heart	I
failure	I
and	O
characterized	O
by	O
low	O
systemic	I
vascular	I
resistance	I
(	O
SVR	I
)	O
index	O
and	O
preserved	O
cardiac	I
index	I
.	O

Twenty-seven	O
symptomatic	I
adult	I
Fontan	I
(	O
SAF	I
)	O
patients	I
who	O
underwent	O
catheterization	I
from	O
2001	O
to	O
2011	O
constituted	O
our	O
study	O
group	O
.	O

Fifty-four	O
predominantly	O
asymptomatic	I
pediatric	I
Fontan	I
(	O
PF	I
)	O
patients	I
who	O
underwent	O
catheterization	I
during	O
the	O
same	O
period	O
were	O
randomly	O
selected	O
to	O
perform	O
a	O
control	O
:	O
case	O
cohort	O
analysis	O
.	O

Clinical	I
comparisons	O
were	O
made	O
between	O
the	O
2	O
groups	O
.	O

The	O
adults	O
were	O
more	O
symptomatic	I
than	O
the	O
PF	I
cohort	O
(	O
New	I
York	I
Heart	I
Association	I
classes	I
I	O
and	O
II	O
or	O
III	O
and	O
IV	O
:	O
48	O
%	O
or	O
52	O
%	O
[	O
SAF	I
]	O
vs	O
94	O
%	O
or	O
6	O
%	O
[	O
PF	I
]	O
,	O
respectively	O
,	O
p	I
<	O
0.01	O
)	O
.	O

SAF	I
versus	O
PF	I
mean	O
catheterization	I
findings	O
were	O
central	I
venous	I
pressure	I
18	O
±	O
6	O
versus	O
14	O
±	O
3	O
mm	O
Hg	O
(	O
p	I
<	O
0.01	O
)	O
,	O
SVR	I
index	O
1,680	O
±	O
368	O
versus	O
1,960	O
±	O
550	O
dyn	O
s	O
/	O
cm	O
(	O
5	O
)	O
/	O
m	O
(	O
2	O
)	O
(	O
p	I
=	O
0.02	O
)	O
,	O
and	O
cardiac	I
index	I
2.7	O
±	O
0.8	O
versus	O
2.8	O
±	O
0.7	O
L	O
/	O
min	O
/	O
m	O
(	O
2	O
)	O
(	O
p	I
=	O
0.25	O
)	O
.	O

By	O
imaging	O
,	O
the	O
SAF	I
cohort	O
demonstrated	O
a	O
greater	O
incidence	I
of	O
abnormal	O
liver	I
texture	O
changes	O
(	O
96	O
%	O
vs	O
75	O
%	O
,	O
p	I
=	O
0.04	O
)	O
and	O
nodularity	I
(	O
77	O
%	O
vs	O
42	O
%	O
,	O
p	I
=	O
0.02	O
)	O
.	O

In	O
conclusion	O
,	O
adult	O
patients	I
with	O
failing	O
Fontan	I
circulation	I
had	O
a	O
lower	O
SVR	I
index	O
and	O
similar	O
cardiac	I
index	I
compared	O
with	O
the	O
pediatric	O
cohort	O
.	O

Liver	I
disease	I
in	O
the	O
adults	O
was	O
more	O
advanced	O
.	O

Our	O
data	O
suggest	O
that	O
Fontan	I
failure	I
is	O
a	O
distinct	O
circulatory	I
derangement	O
with	O
hemodynamic	I
features	O
similar	O
to	O
portal	I
hypertension	I
,	O
albeit	O
with	O
limited	O
ability	O
to	O
augment	O
cardiac	I
output	I
.	O

Predictors	O
of	O
mortality	I
in	O
patients	I
with	O
an	O
implantable	I
cardiac	I
defibrillator	I
:	O
a	O
systematic	O
review	O
and	O
meta-analysis	I
.	O

BACKGROUND	O
:	O

Many	O
current	O
predictors	O
of	O
mortality	I
in	O
heart	I
failure	I
(	O
HF	I
)	O
were	O
evaluated	O
before	O
the	O
use	O
of	O
implantable	I
cardioverter	I
defibrillators	I
(	O
ICDs	I
)	O
.	O

We	O
conducted	O
a	O
meta-analysis	I
to	O
identify	O
factors	O
associated	O
with	O
mortality	I
in	O
ICD-HF	I
patients	I
.	O

METHODS	O
:	O

We	O
searched	O
in	O
MedLine	O
,	O
EMBASE	O
,	O
and	O
CINAHL	O
in	O
May	O
2012	O
.	O

Two	O
reviewers	O
selected	O
citations	O
that	O
included	O
ambulatory	I
ICD	I
patients	I
and	O
addressed	O
the	O
association	O
between	O
any	O
predictor	O
and	O
mortality	I
using	O
multivariable	I
regression	I
.	O

We	O
meta-analyzed	I
mortality	I
using	O
random-effects	I
models	I
.	O

RESULTS	O
:	O

Of	O
10,420	O
studies	O
reviewed	O
,	O
72	O
studies	O
evaluating	O
63	O
predictors	O
on	O
257,692	O
ICD	I
patients	I
proved	O
eligible	O
.	O

High	O
confidence	O
in	O
estimates	O
was	O
found	O
for	O
age	O
(	O
hazard	I
ratio	I
[	O
HR	I
]	O
,	O
1.45	O
for	O
10-year	O
increase	O
;	O
95	O
%	O
confidence	I
interval	I
[	O
CI	I
]	O
,	O
1.35	O
-	O
1.56	O
)	O
,	O
baseline	I
glomerular	I
filtration	I
rate	I
(	O
HR	I
,	O
1.25	O
for	O
15-mL	O
/	O
min	O
decrease	O
;	O
95	O
%	O
CI	I
,	O
1.15	O
-	O
1.35	O
)	O
,	O
chronic	I
obstructive	I
pulmonary	I
disease	I
(	O
HR	I
,	O
1.54	O
;	O
95	O
%	O
CI	I
,	O
1.38	O
-	O
1.71	O
)	O
,	O
diabetes	I
(	O
HR	I
,	O
1.56	O
;	O
95	O
%	O
CI	I
,	O
1.37	O
-	O
1.79	O
)	O
,	O
peripheral	I
vascular	I
disease	I
(	O
HR	I
,	O
1.43	O
;	O
95	O
%	O
CI	I
,	O
1.2	O
-	O
1.72	O
)	O
,	O
left	I
ventricular	I
ejection	I
fraction	I
(	O
HR	I
,	O
0.77	O
for	O
10	O
%	O
increase	O
;	O
95	O
%	O
CI	I
,	O
0.73	O
-	O
0.83	O
)	O
,	O
and	O
appropriate	O
or	O
inappropriate	O
ICD	I
shocks	I
(	O
HR	I
,	O
2.34	O
;	O
95	O
%	O
CI	I
1.59	O
-	O
3.44	O
)	O
New	I
York	I
Heart	I
Association	I
class	I
,	O
atrial	I
fibrillation	I
,	O
and	O
congestive	I
HF	I
were	O
strongly	O
associated	O
with	O
mortality	I
but	O
the	O
confidence	O
in	O
estimates	O
was	O
low	O
.	O

Ischemic	I
cardiomyopathy	I
and	O
male	O
sex	O
were	O
not	O
independent	O
predictors	O
of	O
mortality	I
.	O

CONCLUSIONS	O
:	O

This	O
meta-analysis	I
identified	O
strong	O
reliable	O
mortality	I
predictors	O
in	O
ICD-HF	I
patients	I
.	O

Age	O
,	O
renal	I
dysfunction	I
,	O
chronic	I
obstructive	I
pulmonary	I
disease	I
,	O
diabetes	I
,	O
peripheral	I
vascular	I
disease	I
,	O
decreased	O
left	I
ventricular	I
ejection	I
fraction	I
,	O
and	O
ICD	I
shocks	I
during	O
follow-up	I
were	O
strong	O
predictors	O
of	O
mortality	I
;	O
ischemic	I
cardiomyopathy	I
and	O
male	O
sex	O
were	O
not	O
.	O

Further	O
research	O
is	O
needed	O
to	O
study	O
other	O
potential	O
predictors	O
,	O
particularly	O
biomarkers	I
.	O

Low-dose	O
dopamine	I
or	O
low-dose	O
nesiritide	I
in	O
acute	I
heart	I
failure	I
with	O
renal	I
dysfunction	I
:	O
the	O
ROSE	O
acute	I
heart	I
failure	I
randomized	I
trial	O
.	O

IMPORTANCE	O
:	O

Small	O
studies	O
suggest	O
that	O
low-dose	O
dopamine	I
or	O
low-dose	O
nesiritide	I
may	O
enhance	O
decongestion	O
and	O
preserve	O
renal	I
function	I
in	O
patients	I
with	O
acute	I
heart	I
failure	I
and	O
renal	I
dysfunction	I
;	O
however	O
,	O
neither	O
strategy	O
has	O
been	O
rigorously	O
tested	O
.	O

OBJECTIVE	O
:	O

To	O
test	O
the	O
2	O
independent	O
hypotheses	O
that	O
,	O
compared	O
with	O
placebo	I
,	O
addition	O
of	O
low-dose	O
dopamine	I
(	O
2	O
μg	O
/	O
kg	O
/	O
min	O
)	O
or	O
low-dose	O
nesiritide	I
(	O
0.005	O
μg	O
/	O
kg	O
/	O
min	O
without	O
bolus	I
)	O
to	O
diuretic	I
therapy	I
will	O
enhance	O
decongestion	O
and	O
preserve	O
renal	I
function	I
in	O
patients	I
with	O
acute	I
heart	I
failure	I
and	O
renal	I
dysfunction	I
.	O

DESIGN	O
,	O
SETTING	O
,	O
AND	O
PARTICIPANTS	O
:	O

Multicenter	O
,	O
double-blind	I
,	O
placebo-controlled	I
clinical	I
trial	O
(	O
Renal	I
Optimization	O
Strategies	O
Evaluation	O
[	O
ROSE	O
]	O
)	O
of	O
360	O
hospitalized	I
patients	I
with	O
acute	I
heart	I
failure	I
and	O
renal	I
dysfunction	I
(	O
estimated	I
glomerular	I
filtration	I
rate	I
of	O
15	O
-	O
60	O
mL	O
/	O
min	O
/	O
1.73	O
m2	O
)	O
,	O
randomized	I
within	O
24	O
hours	O
of	O
admission	I
.	O

Enrollment	O
occurred	O
from	O
September	O
2010	O
to	O
March	O
2013	O
across	O
26	O
sites	O
in	O
North	O
America	O
.	O

INTERVENTIONS	O
:	O

Participants	O
were	O
randomized	I
in	O
an	O
open	O
,	O
1:1	O
allocation	O
ratio	O
to	O
the	O
dopamine	I
or	O
nesiritide	I
strategy	O
.	O

Within	O
each	O
strategy	O
,	O
participants	O
were	O
randomized	I
in	O
a	O
double-blind	I
,	O
2:1	O
ratio	O
to	O
active	O
treatment	O
or	O
placebo	I
.	O

The	O
dopamine	I
(	O
n	O
=	O
122	O
)	O
and	O
nesiritide	I
(	O
n	O
=	O
119	O
)	O
groups	O
were	O
independently	O
compared	O
with	O
the	O
pooled	O
placebo	I
group	O
(	O
n	O
=	O
119	O
)	O
.	O

MAIN	O
OUTCOMES	I
AND	O
MEASURES	O
:	O

Coprimary	I
end	I
points	I
included	O
72-hour	O
cumulative	O
urine	O
volume	O
(	O
decongestion	O
end	I
point	I
)	O
and	O
the	O
change	O
in	O
serum	I
cystatin	I
C	I
from	O
enrollment	O
to	O
72	O
hours	O
(	O
renal	I
function	I
end	I
point	I
)	O
.	O

RESULTS	O
:	O

Compared	O
with	O
placebo	I
,	O
low-dose	O
dopamine	I
had	O
no	O
significant	I
effect	O
on	O
72-hour	O
cumulative	O
urine	O
volume	O
(	O
dopamine	I
,	O
8524	O
mL	O
;	O
95	O
%	O
CI	I
,	O
7917	O
-	O
9131	O
vs	O
placebo	I
,	O
8296	O
mL	O
;	O
95	O
%	O
CI	I
,	O
7762	O
-	O
8830	O
;	O
difference	O
,	O
229	O
mL	O
;	O
95	O
%	O
CI	I
,	O
-	O
714	O
to	O
1171	O
mL	O
;	O
P	I
=	O
.59	O
)	O
or	O
on	O
the	O
change	O
in	O
cystatin	I
C	I
level	O
(	O
dopamine	I
,	O
0.12	O
mg	O
/	O
L	O
;	O
95	O
%	O
CI	I
,	O
0.06	O
-	O
0.18	O
vs	O
placebo	I
,	O
0.11	O
mg	O
/	O
L	O
;	O
95	O
%	O
CI	I
,	O
0.06	O
-	O
0.16	O
;	O
difference	O
,	O
0.01	O
;	O
95	O
%	O
CI	I
,	O
-	O
0.08	O
to	O
0.10	O
;	O
P	I
=	O
.72	O
)	O
.	O

Similarly	O
,	O
low-dose	O
nesiritide	I
had	O
no	O
significant	I
effect	O
on	O
72-hour	O
cumulative	O
urine	O
volume	O
(	O
nesiritide	I
,	O
8574	O
mL	O
;	O
95	O
%	O
CI	I
,	O
8014	O
-	O
9134	O
vs	O
placebo	I
,	O
8296	O
mL	O
;	O
95	O
%	O
CI	I
,	O
7762	O
-	O
8830	O
;	O
difference	O
,	O
279	O
mL	O
;	O
95	O
%	O
CI	I
,	O
-	O
618	O
to	O
1176	O
mL	O
;	O
P	I
=	O
.49	O
)	O
or	O
on	O
the	O
change	O
in	O
cystatin	I
C	I
level	O
(	O
nesiritide	I
,	O
0.07	O
mg	O
/	O
L	O
;	O
95	O
%	O
CI	I
,	O
0.01	O
-	O
0.13	O
vs	O
placebo	I
,	O
0.11	O
mg	O
/	O
L	O
;	O
95	O
%	O
CI	I
,	O
0.06	O
-	O
0.16	O
;	O
difference	O
,	O
-	O
0.04	O
;	O
95	O
%	O
CI	I
,	O
-	O
0.13	O
to	O
0.05	O
;	O
P	I
=	O
.36	O
)	O
.	O

Compared	O
with	O
placebo	I
,	O
there	O
was	O
no	O
effect	O
of	O
low-dose	O
dopamine	I
or	O
nesiritide	I
on	O
secondary	I
end	I
points	I
reflective	O
of	O
decongestion	O
,	O
renal	I
function	I
,	O
or	O
clinical	I
outcomes	I
.	O

CONCLUSION	O
AND	O
RELEVANCE	O
:	O

In	O
participants	O
with	O
acute	I
heart	I
failure	I
and	O
renal	I
dysfunction	I
,	O
neither	O
low-dose	O
dopamine	I
nor	O
low-dose	O
nesiritide	I
enhanced	O
decongestion	O
or	O
improved	O
renal	I
function	I
when	O
added	O
to	O
diuretic	I
therapy	I
.	O

Atrial	I
fibrillation	I
and	O
congestive	I
heart	I
failure	I
:	O
a	O
cost	O
analysis	O
of	O
rhythm-control	I
vs.	O
rate-control	I
strategies	O
.	O

BACKGROUND	O
:	O

Atrial	I
fibrillation	I
(	O
AF	I
)	O
is	O
common	O
in	O
patients	I
with	O
heart	I
failure	I
.	O

Rhythm	I
-	O
and	O
rate-control	I
strategies	O
are	O
associated	O
with	O
similar	O
efficacy	O
outcomes	I
.	O

We	O
compared	O
the	O
economic	O
impact	O
of	O
the	O
2	O
treatment	O
strategies	O
in	O
patients	I
with	O
AF	I
and	O
heart	I
failure	I
from	O
the	O
province	O
of	O
Québec	O
,	O
Canada	O
.	O

METHODS	O
:	O

In	O
a	O
substudy	O
of	O
the	O
Atrial	I
Fibrillation	I
and	O
Congestive	I
Heart	I
Failure	I
trial	O
,	O
health	I
care	I
expenditures	O
of	O
patients	I
from	O
Québec	O
randomized	I
to	O
rhythm	I
and	O
rate-control	I
treatment	O
strategies	O
were	O
compared	O
from	O
a	O
single-payer	O
perspective	O
using	O
a	O
cost-minimization	O
approach	O
.	O

In-trial	O
resource	O
utilization	O
and	O
unit	O
costs	O
were	O
estimated	O
from	O
Québec	O
Health	I
Insurance	O
Board	O
databases	O
supplemented	O
by	O
disease-specific	I
costs	O
from	O
the	O
Ontario	O
Case	O
Costing	O
Initiative	O
.	O

RESULTS	O
:	O

In	O
all	O
,	O
304	O
patients	I
were	O
included	O
,	O
aged	O
68	O
±	O
9	O
years	O
;	O
86	O
%	O
male	O
;	O
ejection	I
fraction	I
,	O
26	O
%	O
±	O
6	O
%	O
.	O

Baseline	I
characteristics	O
were	O
similar	O
in	O
rhythm-control	I
(	O
n	O
=	O
149	O
)	O
and	O
rate-control	I
(	O
n	O
=	O
155	O
)	O
groups	O
.	O

Arrhythmia-related	I
costs	O
accounted	O
for	O
45	O
%	O
of	O
total	O
expenditures	O
.	O

Rate-control	I
patients	I
had	O
fewer	O
cardiac	I
procedures	O
(	O
146	O
vs.	O
238	O
,	O
P	I
<	O
0.001	O
)	O
,	O
driven	O
by	O
fewer	O
cardioversions	I
,	O
and	O
lower	O
costs	O
related	O
to	O
antiarrhythmic	I
drugs	I
(	O
CAD	I
$	O
48	O
per	O
patient	I
[	O
95	O
%	O
confidence	I
interval	I
{	O
CI	I
}	O
,	O
$	O
21-$96	O
]	O
vs.	O
$	O
1319	O
per	O
patient	I
[	O
95	O
%	O
CI	I
,	O
$	O
1124-$1522	O
]	O
)	O
.	O

However	O
,	O
these	O
differences	O
were	O
offset	O
by	O
higher	O
expenditures	O
due	O
to	O
hospitalizations	I
for	O
noncardiovascular	I
diagnoses	I
,	O
implantable	I
cardiac	I
arrhythmia	I
devices	I
,	O
and	O
noncardiovascular	I
drugs	I
in	O
the	O
rate-control	I
group	O
.	O

The	O
total	O
cost	O
per	O
patient	I
was	O
not	O
significantly	I
different	O
between	O
rhythm-control	I
(	O
$	O
72,764	O
[	O
95	O
%	O
CI	I
,	O
$	O
61,575-$85,145	O
]	O
)	O
and	O
rate-control	I
(	O
$	O
78,767	O
[	O
95	O
%	O
CI	I
,	O
$	O
67,101-$92,139	O
]	O
)	O
strategies	O
.	O

CONCLUSION	O
:	O

In	O
the	O
study	O
population	O
,	O
the	O
therapeutic	I
strategy	O
used	O
to	O
manage	O
AF	I
in	O
patients	I
with	O
severe	I
heart	I
failure	I
appears	O
to	O
have	O
little	O
influence	O
on	O
the	O
overall	O
financial	O
burden	O
,	O
which	O
remains	O
substantial	O
.	O

Bioinformatic	O
analysis	O
of	O
microarray	I
data	O
reveals	O
several	O
key	O
genes	I
related	O
to	O
heart	I
failure	I
.	O

OBJECTIVES	O
:	O

Heart	I
failure	I
is	O
a	O
major	O
public	O
health	I
problem	O
worldwide	O
.	O

However	O
,	O
the	O
molecular	O
mechanism	O
is	O
still	O
unclear	O
.	O

This	O
study	O
aims	O
to	O
discover	O
differentially	I
expressed	I
genes	I
(	O
DEGs	I
)	O
between	O
non-ischemic	I
or	O
ischemic	I
heart	I
failure	I
samples	O
and	O
healthy	I
control	O
,	O
which	O
may	O
be	O
used	O
for	O
diagnosis	I
and	O
treatment	O
of	O
heart	I
failure	I
.	O

MATERIALS	O
AND	O
METHODS	O
:	O

Gene	I
expression	I
profile	I
GSE9128	O
was	O
downloaded	O
from	O
Gene	I
Expression	I
Omnibus	O
,	O
including	O
3	O
normal	O
samples	O
,	O
4	O
non-ischemic	I
heart	I
failure	I
samples	O
and	O
4	O
ischemic	I
samples	O
.	O

Data	O
processing	O
and	O
differential	I
analysis	I
were	O
carried	O
out	O
with	O
packages	O
of	O
R.	O
Cluster	I
analysis	I
was	O
also	O
performed	O
for	O
all	O
the	O
samples	O
to	O
globally	O
observe	O
the	O
difference	O
among	O
the	O
three	O
groups	O
of	O
samples	O
.	O

Interactors	O
of	O
the	O
DEGs	I
were	O
retrieved	O
with	O
Osprey	O
and	O
then	O
networks	O
were	O
constructed	O
.	O

The	O
overlapping	O
part	O
of	O
the	O
network	O
was	O
selected	O
out	O
using	O
Cytoscape	O
,	O
for	O
which	O
functional	I
enrichment	I
analysis	I
was	O
applied	O
with	O
DAVID	I
tools	O
.	O

RESULTS	O
:	O

A	O
total	O
of	O
293	O
and	O
133	O
DEGs	I
were	O
obtained	O
for	O
non-ischemic	I
and	O
ischemic	I
heart	I
failure	I
,	O
respectively	O
.	O

Two	O
networks	O
were	O
established	O
and	O
then	O
functional	I
enrichment	I
analysis	I
revealed	O
that	O
regulation	O
of	O
programmed	O
cell	I
death	I
was	O
most	O
significantly	I
over-represented	O
in	O
common	O
DEGs	I
.	O

CONCLUSIONS	O
:	O

Genes	I
differentially	O
expressed	O
in	O
non-ischemic	I
and	O
ischemic	I
heart	I
failure	I
can	O
be	O
biomarkers	I
to	O
distinguish	O
the	O
two	O
types	O
of	O
heart	I
failure	I
.	O

Besides	O
,	O
these	O
genes	I
can	O
be	O
targets	O
to	O
develop	O
treatments	O
.	O

Rates	O
of	O
ED	I
visits	O
and	O
of	O
intubations	I
for	O
congestive	I
heart	I
failure	I
declined	O
from	O
1996	O
to	O
2008	O
.	O

OBJECTIVE	O
:	O

Many	O
advances	O
have	O
been	O
made	O
recently	O
in	O
the	O
treatment	O
of	O
congestive	I
heart	I
failure	I
(	O
CHF	I
)	O
.	O

We	O
hypothesize	O
that	O
this	O
should	O
have	O
resulted	O
in	O
fewer	O
CHF	I
patients	I
presenting	O
to	O
the	O
emergency	I
department	I
(	O
ED	I
)	O
and	O
fewer	O
being	O
intubated	I
.	O

DESIGN	O
:	O

Retrospective	I
cohort	I
.	O

SETTING	O
:	O

consecutive	O
patients	I
seen	O
by	O
ED	I
physicians	I
in	O
4	O
suburban	O
hospitals	I
in	O
New	O
Jersey	O
and	O
New	O
York	O
from	O
1996	O
to	O
2008	O
.	O

OBJECTIVE	O
:	O

PROTOCOL	O
:	O

We	O
classified	O
patients	I
as	O
having	O
CHF	I
based	O
on	O
International	O
Classification	O
of	O
Diseases	I
,	O
Ninth	O
Revision	O
,	O
codes	O
.	O

For	O
each	O
year	O
of	O
the	O
study	O
,	O
we	O
determined	O
CHF	I
visit	O
rates	O
(	O
as	O
a	O
percentage	O
of	O
total	O
ED	I
visits	O
)	O
and	O
calculated	O
the	O
percentage	O
of	O
CHF	I
patients	I
intubated	I
.	O

We	O
used	O
the	O
Student	I
t	I
test	I
,	O
calculated	O
95	O
%	O
confidence	I
intervals	I
(	O
CIs	I
)	O
,	O
and	O
performed	O
regression	I
analyses	I
.	O

RESULTS	O
:	O

Of	O
the	O
2,374,428	O
ED	I
visits	O
,	O
32,036	O
(	O
1.3	O
%	O
)	O
were	O
for	O
CHF	I
.	O

The	O
mean	O
age	O
of	O
the	O
CHF	I
patients	I
was	O
76	O
±	O
14	O
years	O
,	O
and	O
57	O
%	O
were	O
female	O
.	O

Congestive	I
heart	I
failure	I
visits	O
declined	O
from	O
1.6	O
%	O
of	O
all	O
ED	I
visits	O
in	O
1996	O
to	O
1.2	O
%	O
in	O
2008	O
,	O
a	O
26	O
%	O
relative	O
decrease	O
(	O
95	O
%	O
CI	I
:	O
21%-30	O
%	O
,	O
P	I
<	O
.001	O
,	O
correlation	I
coefficient	I
R	O
(	O
2	O
)	O
=	O
0.94	O
,	O
P	I
<	O
.001	O
)	O
.	O

Of	O
the	O
CHF	I
patients	I
,	O
778	O
(	O
2.4	O
%	O
)	O
were	O
intubated	I
.	O

Intubation	I
rates	O
declined	O
from	O
3.6	O
%	O
in	O
1996	O
to	O
1.7	O
%	O
in	O
2008	O
,	O
a	O
53	O
%	O
(	O
95	O
%	O
CI	I
:	O
31%-68	O
%	O
,	O
P	I
<	O
.001	O
,	O
R	O
(	O
2	O
)	O
=	O
0.83	O
,	O
P	I
<	O
.001	O
)	O
relative	O
decrease	O
.	O

CONCLUSION	O
:	O

The	O
rates	O
of	O
annual	O
ED	I
visits	O
for	O
CHF	I
and	O
intubation	I
rates	O
declined	O
from	O
1996	O
to	O
2008	O
.	O

These	O
decreases	O
are	O
most	O
likely	O
due	O
to	O
better	O
CHF	I
treatments	O
.	O

Skeletal	I
muscle	I
abnormalities	O
and	O
exercise	I
capacity	I
in	O
adults	O
with	O
a	O
Fontan	I
circulation	I
.	O

OBJECTIVES	O
:	O

The	O
peripheral	I
muscle	I
pump	I
is	O
key	O
in	O
promoting	O
cardiac	I
filling	I
during	O
exercise	O
,	O
especially	O
in	O
subjects	O
who	O
lack	O
a	O
subpulmonary	I
ventricle	I
(	O
the	O
Fontan	I
circulation	I
)	O
.	O

A	O
muscle-wasting	I
syndrome	I
exists	O
in	O
acquired	O
heart	I
failure	I
but	O
has	O
not	O
been	O
assessed	O
in	O
Fontan	I
subjects	O
.	O

We	O
sought	O
to	O
investigate	O
whether	O
adults	O
with	O
the	O
Fontan	I
circulation	I
exhibit	O
reduced	O
skeletal	I
muscle	I
mass	O
and	O
/	O
or	O
metabolic	I
abnormalities	O
.	O

DESIGN	O
AND	O
PATIENTS	I
:	O

Sixteen	O
New	I
York	I
Heart	I
Association	I
Class	I
I	I
/	O
II	I
Fontan	I
adults	O
(	O
30±2	O
years	O
)	O
underwent	O
cardiopulmonary	I
exercise	I
testing	I
and	O
lean	I
mass	I
quantification	I
with	O
dual	I
x-ray	I
absorptiometry	I
(	O
DXA	I
)	O
;	O
eight	O
had	O
calf	O
muscle	I
(31)P	O
magnetic	I
resonance	I
spectroscopy	I
as	O
did	O
eight	O
healthy	I
age-matched	O
and	O
sex-matched	O
controls	O
.	O

DXA	I
results	O
were	O
compared	O
with	O
Australian	O
reference	O
data	O
.	O

SETTING	O
:	O

Single	O
tertiary	O
referral	O
centre	O
.	O

RESULTS	O
:	O

Peak	I
VO2	I
was	O
1.9±0.1	O
L	O
/	O
min	O
(	O
66±3	O
%	O
of	O
predicted	O
values	O
)	O
.	O

Skeletal	I
muscle	I
mass	O
assessed	O
by	O
relative	O
appendicular	O
lean	I
mass	I
index	O
was	O
significantly	I
reduced	O
compared	O
with	O
age-matched	O
and	O
sex-matched	O
reference	O
values	O
(	O
Z-score	I
-	O
1.46±0.22	O
,	O
p	I
<	O
0.0001	O
)	O
.	O

Low	O
skeletal	I
muscle	I
mass	O
correlated	I
with	O
poorer	O
VO2	I
max	I
(	O
r=0.67	I
,	O
p=0.004	I
)	O
.	O

Overall	O
,	O
skeletal	I
muscle	I
mass	O
T-score	I
(	O
derived	O
from	O
comparison	O
with	O
young	O
normal	O
reference	O
mean	O
)	O
was	O
-	O
1.47±0.21	O
;	O
4	O
/	O
16	O
Fontan	I
subjects	O
had	O
sarcopenic	I
range	I
muscle	I
wasting	I
(	O
T-score	I
<	O
-	O
2.0	O
)	O
and	O
9	O
/	O
16	O
had	O
less	O
marked	O
,	O
but	O
clinically	I
significant	I
wasting	O
(	O
T-score	I
<	O
-	O
1.0	O
but	O
≥-2.0	O
)	O
.	O

Muscle	I
aerobic	I
capacity	I
,	O
measured	O
by	O
the	O
rate	O
constant	O
(	O
k	O
)	O
of	O
postexercise	I
phosphocreatine	I
resynthesis	I
,	O
was	O
significantly	I
impaired	O
in	O
Fontan	I
adults	O
versus	O
controls	O
(	O
1.48±0.13	O
vs	O
2.40±0.33	O
min(-1)	O
,	O
p=0.02	I
)	O
.	O

Future	O
of	O
advanced	O
heart	I
failure	I
and	O
mechanical	O
support	O
devices	O
:	O
A	O
Cardiology-Cardiovascular	I
Surgery	I
Consensus	O
Report	O

Heart	I
failure	I
is	O
a	O
progressive	O
disease	I
.	O

A	O
considerable	O
number	O
of	O
patients	I
eventually	O
reach	O
an	O
advanced	O
or	O
terminal	I
phase	O
,	O
in	O
spite	O
of	O
developments	O
in	O
diagnostic	I
procedure	O
,	O
alternative	O
treatments	O
that	O
can	O
slow	O
progression	O
,	O
management	O
,	O
and	O
follow-up	I
.	O

In	O
addition	O
to	O
palliative	I
care	I
of	O
patients	I
in	O
the	O
terminal	I
phase	O
,	O
accurate	O
recognition	O
of	O
advanced	O
disease	I
is	O
vital	O
in	O
the	O
determination	O
of	O
therapeutic	I
options	O
.	O

Overall	O
management	O
of	O
patients	I
with	O
heart	I
failure	I
requires	O
the	O
collaboration	O
of	O
professionals	O
from	O
multiple	O
disciplines	O
.	O

Still	O
,	O
patients	I
with	O
advanced	O
heart	I
failure	I
should	O
be	O
managed	O
by	O
a	O
heart	I
team	O
,	O
as	O
indicated	O
by	O
guidelines	O
;	O
communication	O
and	O
collaboration	O
among	O
cardiologists	I
,	O
cardiovascular	I
surgeons	I
,	O
and	O
other	O
medical	I
staff	O
responsible	O
for	O
patient	I
care	O
is	O
necessary	O
.	O

While	O
our	O
country	O
has	O
physicians	I
experienced	O
in	O
the	O
management	O
of	O
patients	I
with	O
advanced	O
heart	I
failure	I
,	O
these	O
professionals	O
are	O
not	O
distributed	O
evenly	O
across	O
the	O
country	O
,	O
and	O
equitable	O
access	O
to	O
therapeutic	I
options	O
is	O
not	O
provided	O
.	O

Hence	O
,	O
progress	O
has	O
yet	O
to	O
be	O
made	O
regarding	O
appropriate	O
referrals	O
and	O
patient	I
circulation	I
.	O

The	O
aims	O
of	O
the	O
present	O
consensus	O
report	O
are	O
to	O
strengthen	O
the	O
connection	O
between	O
certified	O
,	O
experienced	O
centers	O
and	O
those	O
that	O
care	O
for	O
patients	I
irrespective	O
of	O
disease	I
phase	O
and	O
healthcare	I
staff	O
,	O
as	O
well	O
as	O
to	O
raise	O
awareness	O
and	O
provide	O
information	O
regarding	O
conditions	O
in	O
Turkey	O
.	O

Determination	O
of	O
a	O
predictive	O
cutoff	O
value	O
of	O
NT-proBNP	I
testing	O
for	O
long-term	O
survival	O
in	O
ED	I
patients	I
with	O
acute	I
heart	I
failure	I
.	O

OBJECTIVE	O
:	O

The	O
main	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
a	O
predictive	O
cutoff	O
value	O
for	O
plasma	I
N-terminal	I
pro-B-type	I
natriuretic	I
peptide	I
(	O
NT-proBNP	I
)	O
that	O
could	O
successfully	O
predict	O
the	O
long-term	O
(	O
4-year	O
)	O
survival	O
of	O
patients	I
with	O
acute	I
heart	I
failure	I
(	O
HF	I
)	O
at	O
the	O
time	O
of	O
admission	I
to	O
the	O
emergency	I
department	I
(	O
ED	I
)	O
.	O

To	O
our	O
best	O
knowledge	O
,	O
our	O
study	O
is	O
the	O
first	O
research	O
done	O
to	O
identify	O
a	O
predictive	O
cutoff	O
value	O
for	O
admission	I
NT-proBNP	I
to	O
the	O
prescriptive	O
4-year	O
survival	O
of	O
patients	I
admitted	O
to	O
ED	I
with	O
acute	I
HF	I
diagnosis	I
.	O

METHODS	O
:	O

NT-proBNP	I
levels	O
were	O
measured	O
in	O
plasma	I
obtained	O
from	O
99	O
patients	I
with	O
dyspnea	I
and	O
left	I
ventricular	I
dysfunction	I
upon	O
admission	I
to	O
the	O
ED	I
.	O

The	O
end	I
point	I
was	O
survival	O
from	O
the	O
time	O
of	O
inclusion	O
through	O
4	O
years	O
.	O

RESULTS	O
:	O

The	O
mean	O
age	O
of	O
the	O
patients	I
in	O
this	O
study	O
was	O
71.1	O
±	O
10.3	O
years	O
;	O
50	O
of	O
these	O
patients	I
were	O
female	O
.	O

During	O
the	O
4-year	O
follow-up	I
period	O
,	O
76	O
patients	I
died	O
;	O
survivors	O
were	O
significantly	I
younger	O
than	O
non-survivors	O
(	O
64.26	O
±	O
11.42	O
years	O
vs	O
72.83	O
±	O
11.07	O
years	O
,	O
P	I
=	O
.002	O
)	O
.	O

The	O
optimal	O
NT-proBNP	I
cutoff	O
point	O
for	O
predicting	O
4-year	O
survival	O
at	O
the	O
time	O
of	O
admission	I
was	O
2300	O
pg	O
/	O
mL	O
,	O
which	O
had	O
85.9	O
%	O
sensitivity	I
and	O
39.1	O
%	O
specificity	I
(	O
95	O
%	O
confidence	I
interval	I
,	O
area	I
under	I
the	I
curve	I
:	O
0.639	O
,	O
P	I
=	O
.044	O
)	O
.	O

CONCLUSION	O
:	O

Elevated	O
NT-proBNP	I
levels	O
at	O
the	O
time	O
of	O
admission	I
are	O
a	O
strong	O
and	O
independent	O
predictor	O
of	O
all-cause	I
mortality	I
in	O
patients	I
with	O
acute	I
HF	I
4	O
years	O
after	O
admission	I
.	O

Furthermore	O
,	O
the	O
optimal	O
cutoff	O
level	O
of	O
NT-proBNP	I
used	O
to	O
predict	O
4-year	O
survival	O
had	O
high	O
sensitivity	I
.	O

However	O
,	O
especially	O
in	O
the	O
case	O
of	O
long-term	O
survival	O
,	O
additional	O
prospective	I
,	O
large	O
,	O
and	O
multicenter	O
studies	O
are	O
required	O
to	O
confirm	O
our	O
results	O
.	O

Comparable	O
performance	O
of	O
the	O
Kansas	O
City	O
Cardiomyopathy	I
Questionnaire	O
in	O
patients	I
with	O
heart	I
failure	I
with	I
preserved	I
and	O
reduced	I
ejection	I
fraction	I
.	O

BACKGROUND	O
:	O

Despite	O
the	O
growing	O
epidemic	I
of	O
heart	I
failure	I
with	I
preserved	I
ejection	I
fraction	I
(	O
HFpEF	I
)	O
,	O
no	O
valid	O
measure	O
of	O
patients	I
'	O
health	I
status	O
(	O
symptoms	I
,	O
function	O
,	O
and	O
quality	I
of	I
life	I
)	O
exists	O
.	O

We	O
evaluated	O
the	O
Kansas	O
City	O
Cardiomyopathy	I
Questionnaire	O
(	O
KCCQ	O
)	O
,	O
a	O
validated	O
measure	O
of	O
HF	I
with	I
reduced	I
EF	I
,	O
in	O
patients	I
with	O
HFpEF	I
.	O

METHODS	O
AND	O
RESULTS	O
:	O

Using	O
a	O
prospective	I
HF	I
registry	O
,	O
we	O
dichotomized	O
patients	I
into	O
HF	I
with	I
reduced	I
EF	I
(	O
EF≤	I
40	O
)	O
and	O
HFpEF	I
(	O
EF≥50	I
)	O
.	O

The	O
associations	O
between	O
New	I
York	I
Heart	I
Association	I
class	I
,	O
a	O
commonly	O
used	O
criterion	O
standard	O
,	O
and	O
KCCQ	O
Overall	O
Summary	O
and	O
Total	O
Symptom	I
domains	O
were	O
evaluated	O
using	O
Spearman	I
correlations	I
and	O
2-way	I
ANOVA	I
with	O
differences	O
between	O
patients	I
with	O
HF	I
with	I
reduced	I
EF	I
and	O
HFpEF	I
tested	O
with	O
interaction	O
terms	O
.	O

Predictive	O
validity	O
of	O
the	O
KCCQ	O
Overall	O
Summary	O
scores	O
was	O
assessed	O
with	O
Kaplan-Meier	I
curves	I
for	O
death	I
and	O
all-cause	I
hospitalization	I
.	O

Covariate	I
adjustment	I
was	O
made	O
using	O
Cox	I
proportional	I
hazards	I
models	I
.	O

Internal	O
reliability	O
was	O
assessed	O
with	O
Cronbach	I
's	I
α	I
.	O

Among	O
849	O
patients	I
,	O
200	O
(	O
24	O
%	O
)	O
had	O
HFpEF	I
.	O

KCCQ	O
summary	O
scores	O
were	O
strongly	O
associated	O
with	O
New	I
York	I
Heart	I
Association	I
class	I
in	O
both	O
patients	I
with	O
HFpEF	I
(	O
r=-0.62	I
;	O
P	I
<	O
0.001	O
)	O
and	O
HF	I
with	I
reduced	I
EF	I
(	O
r=-0.55	I
;	O
P=0.27	I
for	O
interaction	O
)	O
.	O

One-year	O
event-free	O
rates	O
by	O
KCCQ	O
category	O
among	O
patients	I
with	O
HFpEF	I
were	O
0	O
to	O
25=13.8	O
%	O
,	O
26	O
to	O
50=59.1	O
%	O
,	O
51	O
to	O
75=73.8	O
%	O
,	O
and	O
76	O
to	O
100=77.8	O
%	O
(	O
log	I
rank	I
P	I
<	O
0.001	O
)	O
,	O
with	O
no	O
significant	I
interaction	O
by	O
EF	I
(	O
P=0.37	I
)	O
.	O

The	O
KCCQ	O
domains	O
demonstrated	O
high	O
internal	O
consistency	O
among	O
patients	I
with	O
HFpEF	I
(	O
Cronbach	I
's	I
α=0.96	I
for	O
overall	O
summary	O
and	O
≥0.69	O
in	O
all	O
subdomains	O
)	O
.	O

CONCLUSIONS	O
:	O

Among	O
patients	I
with	O
HFpEF	I
,	O
the	O
KCCQ	O
seems	O
to	O
be	O
a	O
valid	O
and	O
reliable	O
measure	O
of	O
health	I
status	O
and	O
offers	O
excellent	O
prognostic	I
ability	O
.	O

Future	O
studies	O
should	O
extend	O
and	O
replicate	O
our	O
findings	O
,	O
including	O
the	O
establishment	O
of	O
its	O
responsiveness	O
to	O
clinical	I
change	O
.	O

The	O
role	O
of	O
vasopressin	I
in	O
congestive	I
heart	I
failure	I
.	O

Neurohormonal	I
abnormalities	O
contribute	O
to	O
the	O
pathophysiology	I
of	O
congestive	I
heart	I
failure	I
(	O
CHF	I
)	O
.	O

Successful	O
approaches	O
to	O
improving	O
the	O
prognosis	I
of	O
patients	I
with	O
CHF	I
are	O
based	O
largely	O
on	O
therapeutic	I
interruption	O
of	O
activated	O
neurohormonal	I
systems	I
.	O

The	O
use	O
of	O
antagonists	I
and	O
inhibitors	O
of	O
the	O
renin-angiotensin-aldosterone	I
and	O
sympathetic	I
nervous	I
systems	I
has	O
significantly	I
improved	O
clinical	I
outcomes	I
in	O
CHF	I
.	O

Excessive	O
secretion	O
of	O
arginine	I
vasopressin	I
(	O
AVP	I
)	O
has	O
the	O
potential	O
for	O
deleterious	O
effects	O
on	O
various	O
physiologic	I
processes	O
in	O
CHF	I
Inhibition	O
of	O
AVP	I
through	O
vasopressin	I
receptor	I
antagonist	I
therapy	I
is	O
a	O
potentially	O
beneficial	O
new	O
therapeutic	I
approach	O
to	O
CHF	I
.	O

Trastuzumab-related	I
cardiotoxicity	I
among	O
older	O
patients	I
with	O
breast	I
cancer	I
.	O

The	O
use	O
of	O
trastuzumab	I
in	O
the	O
adjuvant	I
setting	O
improves	O
outcomes	I
but	O
is	O
associated	O
with	O
cardiotoxicity	I
manifested	O
as	O
congestive	I
heart	I
failure	I
(	O
CHF	I
)	O
.	O

The	O
rates	O
and	O
risk	O
factors	O
associated	O
with	O
trastuzumab-related	I
CHF	I
among	O
older	O
patients	I
are	O
unknown	O
.	O

Breast	I
cancer	I
patients	I
at	O
least	O
66	O
years	O
old	O
with	O
full	O
Medicare	O
coverage	O
,	O
diagnosed	I
with	O
stage	O
I-III	O
breast	I
cancer	I
between	O
2005	O
and	O
2009	O
,	O
and	O
treated	O
with	O
chemotherapy	I
were	O
identified	O
in	O
the	O
SEER-Medicare	O
and	O
in	O
the	O
Texas	O
Cancer	O
Registry–Medicare	O
databases	O
.	O

The	O
rates	O
and	O
risk	O
factors	O
associated	O
with	O
CHF	I
were	O
evaluated	O
.	O

Chemotherapy	I
,	O
trastuzumab	I
use	O
,	O
comorbidities	I
,	O
and	O
CHF	I
were	O
identified	O
using	O
International	O
Classification	O
of	O
Diseases	I
,	O
version	O
9	O
,	O
and	O
Healthcare	I
Common	O
Procedure	O
Coding	O
System	O
codes	O
.	O

Analyses	O
included	O
descriptive	I
statistics	I
and	O
Cox	I
proportional	I
hazards	I
models	I
.	O

In	O
total	O
,	O
9,535	O
patients	I
were	O
included	O
,	O
of	O
whom	O
2,203	O
(	O
23.1	O
%	O
)	O
received	O
trastuzumab	I
.	O

Median	O
age	O
of	O
the	O
entire	O
cohort	O
was	O
71	O
years	O
old	O
.	O

Among	O
trastuzumab	I
users	O
,	O
the	O
rate	O
of	O
CHF	I
was	O
29.4	O
%	O
compared	O
with	O
18.9	O
%	O
in	O
nontrastuzumab	I
users	I
(	O
P	I
<	O
.001	O
)	O
.	O

Trastuzumab	I
users	O
were	O
more	O
likely	O
to	O
develop	O
CHF	I
than	O
nontrastuzumab	I
users	I
(	O
hazard	I
ratio	I
[	O
HR	I
]	O
,	O
1.95	O
;	O
95	O
%	O
CI	I
,	O
1.75	O
to	O
2.17	O
)	O
.	O

Among	O
trastuzumab-treated	I
patients	I
,	O
older	O
age	O
(	O
age	O
>	O
80	O
years	O
;	O
HR	I
,	O
1.53	O
;	O
95	O
%	O
CI	I
,	O
1.16	O
to	O
2.10	O
)	O
,	O
coronary	I
artery	I
disease	I
(	O
HR	I
,	O
1.82	O
;	O
95	O
%	O
CI	I
,	O
1.34	O
to	O
2.48	O
)	O
,	O
hypertension	I
(	O
HR	I
,	O
1.24	O
;	O
95	O
%	O
CI	I
,	O
1.02	O
to	O
1.50	O
)	O
,	O
and	O
weekly	O
trastuzumab	I
administration	O
(	O
HR	I
,	O
1.33	O
;	O
95	O
%	O
CI	I
,	O
1.05	O
to	O
1.68	O
)	O
increased	O
the	O
risk	O
of	O
CHF	I
.	O

In	O
this	O
large	O
cohort	O
of	O
older	O
breast	I
cancer	I
patients	I
,	O
the	O
rates	O
of	O
trastuzumb-related	O
CHF	I
are	O
higher	O
than	O
those	O
reported	O
in	O
clinical	I
trials	O
.	O

Among	O
patients	I
treated	O
with	O
trastuzumab	I
,	O
those	O
with	O
cardiac	I
comorbidities	I
and	O
older	O
age	O
may	O
be	O
at	O
higher	O
risk	O
.	O

Further	O
studies	O
need	O
to	O
confirm	O
the	O
role	O
that	O
the	O
frequency	O
of	O
administration	O
plays	O
in	O
the	O
development	O
of	O
trastuzumab-related	I
CHF	I
.	O

Myocardial	I
titin	I
hypophosphorylation	I
importantly	O
contributes	O
to	O
heart	I
failure	I
with	I
preserved	I
ejection	I
fraction	I
in	O
a	O
rat	O
metabolic	I
risk	O
model	O
.	O

BACKGROUND	O
:	O

Obesity	I
and	O
diabetes	I
mellitus	I
are	O
important	O
metabolic	I
risk	O
factors	O
and	O
frequent	O
comorbidities	I
in	O
heart	I
failure	I
with	I
preserved	I
ejection	I
fraction	I
.	O

They	O
contribute	O
to	O
myocardial	I
diastolic	I
dysfunction	I
(	O
DD	I
)	O
through	O
collagen	I
deposition	I
or	O
titin	I
modification	O
.	O

The	O
relative	O
importance	O
for	O
myocardial	I
DD	I
of	O
collagen	I
deposition	I
and	O
titin	I
modification	O
was	O
investigated	O
in	O
obese	I
,	O
diabetic	I
ZSF1	I
rats	O
after	O
heart	I
failure	I
with	I
preserved	I
ejection	I
fraction	I
development	O
at	O
20	O
weeks	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O

Four	O
groups	O
of	O
rats	O
(	O
Wistar-Kyoto	O
,	O
n=11	O
;	O
lean	O
ZSF1	I
,	O
n=11	O
;	O
obese	I
ZSF1	I
,	O
n=11	O
,	O
and	O
obese	I
ZSF1	I
with	O
high-fat	O
diet	O
,	O
n=11	O
)	O
were	O
followed	I
up	I
for	O
20	O
weeks	O
with	O
repeat	O
metabolic	I
,	O
renal	I
,	O
and	O
echocardiographic	I
evaluations	O
and	O
hemodynamically	I
assessed	O
at	O
euthanization	I
.	O

Myocardial	I
collagen	I
,	O
collagen	I
cross-linking	I
,	O
titin	I
isoforms	I
,	O
and	O
phosphorylation	I
were	O
also	O
determined	O
.	O

Resting	I
tension	I
(Fpassive)-sarcomere	I
length	I
relations	I
were	O
obtained	O
in	O
small	O
muscle	I
strips	O
before	O
and	O
after	O
KCl-KI	I
treatment	O
,	O
which	O
unanchors	O
titin	I
and	O
allows	O
contributions	O
of	O
titin	I
and	O
extracellular	I
matrix	I
to	O
Fpassive	I
to	O
be	O
discerned	O
.	O

At	O
20	O
weeks	O
,	O
the	O
lean	O
ZSF1	I
group	O
was	O
hypertensive	I
,	O
whereas	O
both	O
obese	I
ZSF1	I
groups	O
were	O
hypertensive	I
and	O
diabetic	I
.	O

Only	O
the	O
obese	I
ZSF1	I
groups	O
had	O
developed	O
heart	I
failure	I
with	I
preserved	I
ejection	I
fraction	I
,	O
which	O
was	O
evident	O
from	O
increased	O
lung	I
weight	O
,	O
preserved	I
left	I
ventricular	I
ejection	I
fraction	I
,	O
and	O
left	I
ventricular	I
DD	I
.	O

The	O
underlying	O
myocardial	I
DD	I
was	O
obvious	O
from	O
high	O
muscle	I
strip	O
stiffness	O
,	O
which	O
was	O
largely	O
(	O
±80	O
%	O
)	O
attributable	O
to	O
titin	I
hypophosphorylation	I
.	O

The	O
latter	O
occurred	O
specifically	O
at	O
the	O
S3991	I
site	O
of	O
the	O
elastic	O
N2Bus	I
segment	O
and	O
at	O
the	O
S12884	I
site	O
of	O
the	O
PEVK	I
segment	O
.	O

CONCLUSIONS	O
:	O

Obese	I
ZSF1	I
rats	O
developed	O
heart	I
failure	I
with	I
preserved	I
ejection	I
fraction	I
during	O
a	O
20-week	O
time	O
span	O
.	O

Titin	I
hypophosphorylation	I
importantly	O
contributed	O
to	O
the	O
underlying	O
myocardial	I
DD	I
.	O

Comments	O
on	O
the	O
role	O
of	O
the	O
emergency	I
department	I
in	O
acute	I
heart	I
failure	I
clinical	I
trials-Enriching	O
patient	I
identification	O
and	O
enrollment	O
by	O
Collins	O
et	O
al	O
.	O

As	O
the	O
authors	O
suggest	O
,	O
patient	I
categorization	O
in	O
the	O
emergency	I
department	I
is	O
perhaps	O
the	O
single	O
most	O
important	O
component	O
that	O
is	O
not	O
focused	O
on	O
in	O
modern	O
acute	I
heart	I
failure	I
(	O
AHF	I
)	O
clinical	I
studies	O
.	O

However	O
,	O
patients	I
with	O
AHF	I
are	O
highly	O
heterogeneous	O
,	O
and	O
appropriate	O
risk	I
stratification	I
is	O
essential	O
in	O
conducting	O
studies	O
in	O
this	O
area	O
.	O

Troponin	I
T	I
and	O
N-terminal	I
pro-B-type	I
natriuretic	I
peptide	I
:	O
a	O
biomarker	I
approach	O
to	O
predict	O
heart	I
failure	I
risk--the	O
atherosclerosis	I
risk	O
in	O
communities	O
study	O
.	O

BACKGROUND	O
:	O

Among	O
the	O
various	O
cardiovascular	I
diseases	I
,	O
heart	I
failure	I
(	O
HF	I
)	O
is	O
projected	O
to	O
have	O
the	O
largest	O
increases	O
in	O
incidence	I
over	O
the	O
coming	O
decades	O
;	O
therefore	O
,	O
improving	O
HF	I
prediction	O
is	O
of	O
significant	I
value	O
.	O

We	O
evaluated	O
whether	O
cardiac	I
troponin	I
T	I
(	O
cTnT	I
)	O
measured	O
with	O
a	O
high-sensitivity	O
assay	O
and	O
N-terminal	I
pro-B-type	I
natriuretic	I
peptide	I
(	O
NT-proBNP	I
)	O
,	O
biomarkers	I
strongly	O
associated	O
with	O
incident	O
HF	I
,	O
improve	O
HF	I
risk	O
prediction	O
in	O
the	O
Atherosclerosis	I
Risk	O
in	O
Communities	O
(	O
ARIC	O
)	O
study	O
.	O

METHODS	O
:	O

Using	O
sex-specific	O
models	O
,	O
we	O
added	O
cTnT	I
and	O
NT-proBNP	I
to	O
age	O
and	O
race	O
(	O
laboratory	O
report	O
model	O
)	O
and	O
to	O
the	O
ARIC	O
HF	I
model	O
(	O
includes	O
age	O
,	O
race	O
,	O
systolic	I
blood	I
pressure	I
,	O
antihypertensive	I
medication	I
use	O
,	O
current	O
/	O
former	O
smoking	O
,	O
diabetes	I
,	O
body	I
mass	I
index	I
,	O
prevalent	O
coronary	I
heart	I
disease	I
,	O
and	O
heart	I
rate	I
)	O
in	O
9868	O
participants	O
without	O
prevalent	O
HF	I
;	O
area	I
under	I
the	I
receiver	I
operating	I
characteristic	I
curve	I
(	O
AUC	I
)	O
,	O
integrated	I
discrimination	I
improvement	I
,	O
net	I
reclassification	I
improvement	I
(	O
NRI	I
)	O
,	O
and	O
model	O
fit	O
were	O
described	O
.	O

RESULTS	O
:	O

Over	O
a	O
mean	O
follow-up	I
of	O
10.4	O
years	O
,	O
970	O
participants	O
developed	O
incident	O
HF	I
.	O

Adding	O
cTnT	I
and	O
NT-proBNP	I
to	O
the	O
ARIC	O
HF	I
model	O
significantly	I
improved	O
all	O
statistical	O
parameters	O
(	O
AUCs	I
increased	O
by	O
0.040	O
and	O
0.057	O
;	O
the	O
continuous	O
NRIs	I
were	O
50.7	O
%	O
and	O
54.7	O
%	O
in	O
women	O
and	O
men	O
,	O
respectively	O
)	O
.	O

Interestingly	O
,	O
the	O
simpler	O
laboratory	O
report	O
model	O
was	O
statistically	O
no	O
different	O
than	O
the	O
ARIC	O
HF	I
model	O
.	O

CONCLUSIONS	O
:	O

cTnT	I
and	O
NT-proBNP	I
have	O
significant	I
value	O
in	O
HF	I
risk	O
prediction	O
.	O

A	O
simple	O
sex-specific	O
model	O
that	O
includes	O
age	O
,	O
race	O
,	O
cTnT	I
,	O
and	O
NT-proBNP	I
(	O
which	O
can	O
be	O
incorporated	O
in	O
a	O
laboratory	O
report	O
)	O
provides	O
a	O
good	O
model	O
,	O
whereas	O
adding	O
cTnT	I
and	O
NT-proBNP	I
to	O
clinical	I
characteristics	O
results	O
in	O
an	O
excellent	O
HF	I
prediction	O
model	O
.	O

Physician	I
volume	O
,	O
specialty	O
,	O
and	O
outcomes	I
of	O
care	O
for	O
patients	I
with	O
heart	I
failure	I
.	O

BACKGROUND	O
:	O

There	O
is	O
an	O
urgent	O
need	O
to	O
improve	O
outcomes	I
and	O
reduce	O
costs	O
for	O
patients	I
with	O
heart	I
failure	I
(	O
HF	I
)	O
.	O

Physician	I
volume	O
is	O
associated	O
with	O
better	O
outcomes	I
for	O
patients	I
undergoing	O
procedures	O
,	O
but	O
its	O
association	O
with	O
outcomes	I
for	O
medically	I
managed	O
diseases	I
,	O
such	O
as	O
HF	I
,	O
is	O
not	O
well	O
understood	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O

We	O
used	O
Medicare	O
inpatient	I
data	O
in	O
2009	O
to	O
examine	O
all	O
HF	I
admissions	I
to	O
acute	I
care	O
hospitals	I
in	O
the	O
United	O
States	O
.	O

We	O
divided	O
physicians	I
into	O
quintiles	O
according	O
to	O
their	O
volume	O
of	O
patients	I
with	O
HF	I
.	O

We	O
used	O
patient-level	I
regression	O
to	O
compare	O
30-day	O
risk-adjusted	O
mortality	I
,	O
readmissions	I
,	O
and	O
costs	O
across	O
volume	O
groups	O
,	O
controlling	O
for	O
patient	I
,	O
physician	I
,	O
and	O
hospital	I
characteristics	O
.	O

We	O
examined	O
physician	I
volume	O
within	O
strata	O
of	O
hospital	I
volume	O
and	O
physician	I
specialty	O
.	O

Patients	I
cared	O
for	O
by	O
the	O
high-volume	O
physicians	I
had	O
lower	O
mortality	I
than	O
those	O
by	O
the	O
low-volume	O
physicians	I
(	O
8.9	O
%	O
versus	O
9.7	O
%	O
;	O
P	I
<	O
0.001	O
)	O
;	O
this	O
relationship	O
was	O
strongest	O
in	O
low-volume	O
hospitals	I
.	O

In	O
contrast	O
,	O
patients	I
cared	O
for	O
by	O
high-volume	O
physicians	I
had	O
higher	O
readmission	I
rates	O
(	O
25.8	O
%	O
versus	O
21.5	O
%	O
;	O
P	I
<	O
0001	O
)	O
;	O
this	O
relationship	O
was	O
similar	O
across	O
hospital	I
volume	O
groups	O
.	O

Finally	O
,	O
costs	O
were	O
higher	O
for	O
the	O
high-volume	O
physicians	I
(	O
$	O
8982	O
versus	O
$	O
8731	O
;	O
P=0.002	I
,	O
a	O
difference	O
that	O
was	O
consistent	O
across	O
hospital	I
volume	O
groups	O
)	O
.	O

The	O
relationship	O
between	O
physician	I
volume	O
and	O
mortality	I
was	O
strongest	O
for	O
internists	I
(	O
9.2	O
%	O
versus	O
10.6	O
%	O
;	O
P	I
<	O
0.001	O
)	O
and	O
weakest	O
for	O
cardiologists	I
(	O
6.4	O
%	O
versus	O
6.7	O
%	O
;	O
P=0.485	I
)	O
.	O

CONCLUSIONS	O
:	O

Physician	I
volume	O
is	O
associated	O
with	O
lower	O
mortality	I
for	O
HF	I
,	O
particularly	O
in	O
low-volume	O
institutions	O
and	O
among	O
noncardiologist	O
physicians	I
.	O

Our	O
findings	O
suggest	O
that	O
clinician	I
expertise	O
may	O
play	O
an	O
important	O
role	O
in	O
HF	I
care	O
.	O

